<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420300891</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112122</dc:identifier><eid>1-s2.0-S0223523420300891</eid><prism:doi>10.1016/j.ejmech.2020.112122</prism:doi><pii>S0223-5234(20)30089-1</pii><dc:title>Allosteric inhibitors of the STAT3 signaling pathway </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>190</prism:volume><prism:startingPage>112122</prism:startingpage><prism:pageRange>112122</prism:pagerange><articleNumber>112122</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-03-15</prism:coverdate><prism:coverDisplayDate>15 March 2020</prism:coverdisplaydate><prism:copyright>Â© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Qin, Junhong</dc:creator><dc:creator>Shen, Xiaofei</dc:creator><dc:creator>Zhang, Jian</dc:creator><dc:creator>Jia, Da</dc:creator><dc:description>
                  Over-expression and/or hyperactivation of signal transducer and activator of transcription 3 (STAT3) signaling are found in various human diseases, including cancer, autoimmune disorders, and inflammatory diseases. Therefore, STAT3 represents a highly promising therapeutic target for the treatment of these diseases. However, the traditional orthosteric inhibitors of STAT3 exhibit limited clinical efficacy, with low selectivity, numerous side effects, and emerging acquired resistance. Allosteric inhibitors targeting STAT3 or its upstream molecules have emerged as a promising approach to overcome these barriers. In this review, we summarize the recent advances in the development of these inhibitors as well as their applications.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>STAT3</dcterms:subject><dcterms:subject>Cancer</dcterms:subject><dcterms:subject>Autoimmune/inflammatory diseases</dcterms:subject><dcterms:subject>Allosteric inhibitors</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420300891" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420300891" rel="scidir"/></link></coredata><objects><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="548" height="202" size="39998">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="561" size="88598">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="543" height="301" size="55554">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="118" size="18332">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="625" height="253" size="61738">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="548" height="179" size="40220">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="548" height="187" size="42155">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="552" height="189" size="29744">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="548" height="189" size="42618">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="81" size="10028">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="208" height="164" size="8225">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="121" size="10941">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="52" size="4173">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="89" size="13978">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="72" size="8318">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="75" size="10248">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="75" size="4676">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="76" size="10672">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2429" height="897" size="387451">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3155" height="2483" size="645097">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2404" height="1331" size="516799">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="522" size="137149">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2768" height="1122" size="503329">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2429" height="795" size="380754">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2429" height="827" size="414505">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2444" height="835" size="201712">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2429" height="838" size="427926">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1200486">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420300891-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85079286146</scopus-id><scopus-eid>2-s2.0-85079286146</scopus-eid><pubmed-id>32066011</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85079286146" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200207">2020-02-07</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200207">2020-02-07</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200214">2020-02-14</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200214">2020-02-14</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-05-27T20:45:03</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420300891</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30089-1</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420300891</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112122</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00031</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20201215">2020-12-15T13:19:43.015643Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200315</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1581066184">2020-02-07T09:03:04.993582Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst nomenclature primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>190</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>190</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 190</xocs:vol-iss-suppl-text>
      <xocs:sort-order>6</xocs:sort-order>
      <xocs:first-fp>112122</xocs:first-fp>
      <xocs:article-number>112122</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112122</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20200315</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 March 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-03-15</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review Papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>Â© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>ALLOSTERICINHIBITORSSTAT3SIGNALINGPATHWAY</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>QIN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>J</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:nomenclature">
            <xocs:item-toc-section-title>Abbreviation table</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Orthosteric inhibitors <ce:italic>vs</ce:italic> allosteric inhibitors</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Allosteric inhibitors of cell surface receptors</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Allosteric kinases inhibitors</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Allosteric JAKs inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Allosteric Abl inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Allosteric Src inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>5</xocs:item-toc-label>
            <xocs:item-toc-section-title>Direct and allosteric inhibitors of STAT3</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>6</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions and prospects</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgment</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>736</xocs:ref-first-fp>
            <xocs:ref-last-lp>746</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>AIGNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>27</xocs:ref-first-fp>
            <xocs:ref-last-lp>34</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>ZHUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1924</xocs:ref-first-fp>
            <xocs:ref-last-lp>1931</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>DEBNATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6645</xocs:ref-first-fp>
            <xocs:ref-last-lp>6668</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>234</xocs:ref-first-fp>
            <xocs:ref-last-lp>248</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>LAUDISI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1787</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>YUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>17663</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>BANERJEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2570</xocs:ref-first-fp>
            <xocs:ref-last-lp>2578</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>AVALLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>42</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>GOUGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1713</xocs:ref-first-fp>
            <xocs:ref-last-lp>1716</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>4957</xocs:ref-first-fp>
            <xocs:ref-last-lp>4969</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>LAZO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>171</xocs:ref-first-fp>
            <xocs:ref-last-lp>181</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>E2708</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>KREBS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>378</xocs:ref-first-fp>
            <xocs:ref-last-lp>387</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>CROKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>414</xocs:ref-first-fp>
            <xocs:ref-last-lp>422</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>LONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>99</xocs:ref-first-fp>
            <xocs:ref-last-lp>104</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>FURTEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>308</xocs:ref-first-fp>
            <xocs:ref-last-lp>318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>646</xocs:ref-first-fp>
            <xocs:ref-last-lp>651</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>XIONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1037</xocs:ref-first-fp>
            <xocs:ref-last-lp>1046</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>642</xocs:ref-first-fp>
            <xocs:ref-last-lp>648</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>506</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>KUSABA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1445</xocs:ref-first-fp>
            <xocs:ref-last-lp>1451</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>DOBI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>28</xocs:ref-first-fp>
            <xocs:ref-last-lp>36</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>DIAZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>20</xocs:ref-first-fp>
            <xocs:ref-last-lp>28</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>11243</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>MIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>918</xocs:ref-first-fp>
            <xocs:ref-last-lp>925</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-article-number>BSR20170650</xocs:ref-article-number>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>207</xocs:ref-first-fp>
            <xocs:ref-last-lp>221</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>47</xocs:ref-first-fp>
            <xocs:ref-last-lp>61</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>5036</xocs:ref-first-fp>
            <xocs:ref-last-lp>5043</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>MARZEC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>20852</xocs:ref-first-fp>
            <xocs:ref-last-lp>20857</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5952</xocs:ref-first-fp>
            <xocs:ref-last-lp>5966</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>SANSONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1005</xocs:ref-first-fp>
            <xocs:ref-last-lp>1014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1275</xocs:ref-first-fp>
            <xocs:ref-last-lp>1283</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>LEPPKES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>57</xocs:ref-first-fp>
            <xocs:ref-last-lp>66</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>HILLMER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>15</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>MIYOSHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>108</xocs:ref-first-fp>
            <xocs:ref-last-lp>117</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>5</xocs:ref-first-fp>
            <xocs:ref-last-lp>10</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>ROSENZWEIG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>71</xocs:ref-first-fp>
            <xocs:ref-last-lp>98</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1922</xocs:ref-first-fp>
            <xocs:ref-last-lp>1933</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-last-lp>68</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>DOKHOLYAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>6463</xocs:ref-first-fp>
            <xocs:ref-last-lp>6487</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>NUSSINOV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>447</xocs:ref-first-fp>
            <xocs:ref-last-lp>455</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>GORMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>359</xocs:ref-first-fp>
            <xocs:ref-last-lp>384</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>6503</xocs:ref-first-fp>
            <xocs:ref-last-lp>6515</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>LISI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>123</xocs:ref-first-fp>
            <xocs:ref-last-lp>130</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>WOOTTEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>630</xocs:ref-first-fp>
            <xocs:ref-last-lp>644</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>51</xocs:ref-first-fp>
            <xocs:ref-last-lp>54</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>DAVIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1046</xocs:ref-first-fp>
            <xocs:ref-last-lp>1051</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>YUEH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>6512</xocs:ref-first-fp>
            <xocs:ref-last-lp>6524</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>OSTREM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>548</xocs:ref-first-fp>
            <xocs:ref-last-lp>551</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>DANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>502</xocs:ref-first-fp>
            <xocs:ref-last-lp>508</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>PRICER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>584</xocs:ref-first-fp>
            <xocs:ref-last-lp>589</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>BRONTE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>300</xocs:ref-first-fp>
            <xocs:ref-last-lp>313</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>4702</xocs:ref-first-fp>
            <xocs:ref-last-lp>4711</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>SUNDARESAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1103</xocs:ref-first-fp>
            <xocs:ref-last-lp>1110</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>NIEDERST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>3924</xocs:ref-first-fp>
            <xocs:ref-last-lp>3933</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>JIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>129</xocs:ref-first-fp>
            <xocs:ref-last-lp>132</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>TO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>926</xocs:ref-first-fp>
            <xocs:ref-last-lp>943</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>CARLINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2627</xocs:ref-first-fp>
            <xocs:ref-last-lp>2634</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>CAPORUSCIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1545</xocs:ref-first-fp>
            <xocs:ref-last-lp>1553</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>CROSS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>201</xocs:ref-first-fp>
            <xocs:ref-last-lp>207</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-article-number>e76551</xocs:ref-article-number>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5189</xocs:ref-first-fp>
            <xocs:ref-last-lp>5199</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>VILLANUEVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1824</xocs:ref-first-fp>
            <xocs:ref-last-lp>1826</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>BONO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>477</xocs:ref-first-fp>
            <xocs:ref-last-lp>488</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>OSHEA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>111</xocs:ref-first-fp>
            <xocs:ref-last-lp>115</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>OHARE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>6987</xocs:ref-first-fp>
            <xocs:ref-last-lp>6993</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>BUCHERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>939</xocs:ref-first-fp>
            <xocs:ref-last-lp>951</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>XIONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>926</xocs:ref-first-fp>
            <xocs:ref-last-lp>957</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>PULS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>566</xocs:ref-first-fp>
            <xocs:ref-last-lp>578</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>BUCHERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>939</xocs:ref-first-fp>
            <xocs:ref-last-lp>951</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>LIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>571</xocs:ref-first-fp>
            <xocs:ref-last-lp>580</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>MIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>27261</xocs:ref-first-fp>
            <xocs:ref-last-lp>27270</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>TOKARSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>11061</xocs:ref-first-fp>
            <xocs:ref-last-lp>11074</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>MOSLIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>700</xocs:ref-first-fp>
            <xocs:ref-last-lp>712</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>WROBLESKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>8973</xocs:ref-first-fp>
            <xocs:ref-last-lp>8995</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>ra55</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79">
            <xocs:ref-normalized-surname>SHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1578</xocs:ref-first-fp>
            <xocs:ref-last-lp>1586</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>COPPO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>171</xocs:ref-first-fp>
            <xocs:ref-last-lp>179</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>HAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>108</xocs:ref-first-fp>
            <xocs:ref-last-lp>114</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>KANTARJIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>913</xocs:ref-first-fp>
            <xocs:ref-last-lp>923</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>ADRIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>95</xocs:ref-first-fp>
            <xocs:ref-last-lp>102</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>WYLIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>733</xocs:ref-first-fp>
            <xocs:ref-last-lp>737</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>HUGHES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2315</xocs:ref-first-fp>
            <xocs:ref-last-lp>2326</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>81</xocs:ref-first-fp>
            <xocs:ref-last-lp>93</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>CRESPAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3999</xocs:ref-first-fp>
            <xocs:ref-last-lp>4008</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>VIGNAROLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>168</xocs:ref-first-fp>
            <xocs:ref-last-lp>175</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>GELMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>801</xocs:ref-first-fp>
            <xocs:ref-last-lp>807</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>SHUKLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>3397</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>YEH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>795</xocs:ref-first-fp>
            <xocs:ref-last-lp>801</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-normalized-surname>NAMANJA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>579</xocs:ref-first-fp>
            <xocs:ref-last-lp>589</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93">
            <xocs:ref-normalized-surname>SHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>17471</xocs:ref-first-fp>
            <xocs:ref-last-lp>17486</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>BUTTURINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1885</xocs:ref-first-fp>
            <xocs:ref-last-lp>1893</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>MINUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>13085</xocs:ref-first-fp>
            <xocs:ref-last-lp>13089</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>HARDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>706</xocs:ref-first-fp>
            <xocs:ref-last-lp>715</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>FEHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>98</xocs:ref-first-fp>
            <xocs:ref-last-lp>103</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref98">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>451</xocs:ref-first-fp>
            <xocs:ref-last-lp>458</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref99">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>6405</xocs:ref-first-fp>
            <xocs:ref-last-lp>6421</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref100">
            <xocs:ref-normalized-surname>AKBAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1355</xocs:ref-first-fp>
            <xocs:ref-last-lp>1363</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref101">
            <xocs:ref-normalized-surname>AHN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>465</xocs:ref-first-fp>
            <xocs:ref-last-lp>469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref102">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-last-lp>68</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref103">
            <xocs:ref-normalized-surname>PENDERGRASS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>31</xocs:ref-first-fp>
            <xocs:ref-last-lp>38</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref104">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>443</xocs:ref-first-fp>
            <xocs:ref-last-lp>451</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref105">
            <xocs:ref-normalized-surname>BRAUNSTEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>34133</xocs:ref-first-fp>
            <xocs:ref-last-lp>34140</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref106">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>8150</xocs:ref-first-fp>
            <xocs:ref-last-lp>8155</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref107">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>QINX2020X112122</xocs:refkey3>
         <xocs:refkey4ai>QINX2020X112122XJ</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-02-14T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-02-14T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">Â© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-02-11T01:30:57.734Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-acronym>SPDST</xocs:funding-agency-acronym>
            <xocs:funding-agency>Department of Science and Technology of Sichuan Province</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004829</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30089-1</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420300891</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420300891</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112122</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2020-12-15T13:19:43.015643Z</xocs:timestamp>
         <xocs:cover-date-start>2020-03-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/MAIN/application/pdf/9c7be3345c312aaec314eff29a6fb598/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2131616</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>10</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420300891-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/PREVIEW/image/png/1ecd8bfd2bf164287e1c506299b886b3/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>41977</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr6/DOWNSAMPLED/image/jpeg/500a721cf4fed2cd87bf890126c42193/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39998</xocs:filesize>
               <xocs:pixel-height>202</xocs:pixel-height>
               <xocs:pixel-width>548</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr2/DOWNSAMPLED/image/jpeg/6b48165abf2e1b5db874ae9f4861c8b8/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>88598</xocs:filesize>
               <xocs:pixel-height>561</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr1/DOWNSAMPLED/image/jpeg/b901567d2e66bb2bc15c205bc55de37d/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>55554</xocs:filesize>
               <xocs:pixel-height>301</xocs:pixel-height>
               <xocs:pixel-width>543</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/fx1/DOWNSAMPLED/image/jpeg/1bb53438ef7d2a2acf3af31183159f85/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18332</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr7/DOWNSAMPLED/image/jpeg/6331229ede0eb56d14522c6931728930/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>61738</xocs:filesize>
               <xocs:pixel-height>253</xocs:pixel-height>
               <xocs:pixel-width>625</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr3/DOWNSAMPLED/image/jpeg/26814a8992dba413d40926a1b805b922/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40220</xocs:filesize>
               <xocs:pixel-height>179</xocs:pixel-height>
               <xocs:pixel-width>548</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr4/DOWNSAMPLED/image/jpeg/fe101a63824606245b95818e1c092e9a/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>42155</xocs:filesize>
               <xocs:pixel-height>187</xocs:pixel-height>
               <xocs:pixel-width>548</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr8/DOWNSAMPLED/image/jpeg/0abc80082aac261cd7bee3cb2a55e1ca/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29744</xocs:filesize>
               <xocs:pixel-height>189</xocs:pixel-height>
               <xocs:pixel-width>552</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr5/DOWNSAMPLED/image/jpeg/b38c99422150adfc5eaa1beac32bffad/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>42618</xocs:filesize>
               <xocs:pixel-height>189</xocs:pixel-height>
               <xocs:pixel-width>548</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr6/THUMBNAIL/image/gif/859c3f2f1b388b0706538e56642e7377/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10028</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr2/THUMBNAIL/image/gif/a1c39a0b869cd51eaa4b4234fe39f070/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8225</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>208</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr1/THUMBNAIL/image/gif/1aec1f0ed263be183e6c5d487ba742cb/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10941</xocs:filesize>
               <xocs:pixel-height>121</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/fx1/THUMBNAIL/image/gif/45e2a90af583997705ee68c75dc5f10e/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4173</xocs:filesize>
               <xocs:pixel-height>52</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr7/THUMBNAIL/image/gif/fae878555f2a3a554ea18158fd8e9802/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13978</xocs:filesize>
               <xocs:pixel-height>89</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr3/THUMBNAIL/image/gif/704100daf46984b9ebebbcc523cfcb36/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8318</xocs:filesize>
               <xocs:pixel-height>72</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr4/THUMBNAIL/image/gif/35bd0c37109787f0fa2327f8c443d233/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10248</xocs:filesize>
               <xocs:pixel-height>75</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr8/THUMBNAIL/image/gif/f4d9fcfc757383283a75a3fb64a49a33/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4676</xocs:filesize>
               <xocs:pixel-height>75</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr5/THUMBNAIL/image/gif/cf0894f554e065dd1f524ef62406f117/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10672</xocs:filesize>
               <xocs:pixel-height>76</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr6/HIGHRES/image/jpeg/63e5d10ae7cd1138476705af5b8a57d6/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>387451</xocs:filesize>
               <xocs:pixel-height>897</xocs:pixel-height>
               <xocs:pixel-width>2429</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr2/HIGHRES/image/jpeg/c526c4d8fff4764fa6f3f3a28d5d68b5/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>645097</xocs:filesize>
               <xocs:pixel-height>2483</xocs:pixel-height>
               <xocs:pixel-width>3155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr1/HIGHRES/image/jpeg/d70abe0181ec29ae281cd4fd893f0c12/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>516799</xocs:filesize>
               <xocs:pixel-height>1331</xocs:pixel-height>
               <xocs:pixel-width>2404</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/fx1/HIGHRES/image/jpeg/2f4b8bfe1dd17323bb098a39fd85c065/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>137149</xocs:filesize>
               <xocs:pixel-height>522</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr7/HIGHRES/image/jpeg/fac3758410bf0e92729f5f3c994a44df/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>503329</xocs:filesize>
               <xocs:pixel-height>1122</xocs:pixel-height>
               <xocs:pixel-width>2768</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr3/HIGHRES/image/jpeg/9edd711ed231fa7f5e1d5c3c81cb24f2/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>380754</xocs:filesize>
               <xocs:pixel-height>795</xocs:pixel-height>
               <xocs:pixel-width>2429</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr4/HIGHRES/image/jpeg/8309ea32e19e1436fac3c1b279552eda/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>414505</xocs:filesize>
               <xocs:pixel-height>827</xocs:pixel-height>
               <xocs:pixel-width>2429</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr8/HIGHRES/image/jpeg/50348378a7ec6f1f5cdc490fae3f3dd1/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>201712</xocs:filesize>
               <xocs:pixel-height>835</xocs:pixel-height>
               <xocs:pixel-width>2444</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420300891/gr5/HIGHRES/image/jpeg/71fe351b44dd919da7dad69a2bcffd09/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>427926</xocs:filesize>
               <xocs:pixel-height>838</xocs:pixel-height>
               <xocs:pixel-width>2429</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420300891-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1200486</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10PQW2952FS/MAIN/application/pdf/69252f8b172063031464df15ae6be8a1/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112122</aid>
            <ce:article-number>112122</ce:article-number>
            <ce:pii>S0223-5234(20)30089-1</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112122</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig.Â 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">The STAT3 signaling pathway. Binding of surface receptors to growth factors (like EGF) or cytokines (such as IL-6) leads to recruitment and/or activation of receptor tyrosine kinases and intracellular non-receptor tyrosine kinases. These tyrosine kinases subsequently phosphorylate STAT3 at Tyr705. Phosphorylated STAT3 then forms a dimer, and translocates to the nucleus, where it binds to specific DNA sequence and induces the transcription of target genes. The activation of STAT3 signaling is negatively regulated by SHP-1/2 and SOCS.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig.Â 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420300891/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig.Â 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Chemical structures of allosteric inhibitors targeting upstream kinases in the STAT3 signaling pathway.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig.Â 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420300891/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig.Â 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Detailed interactions between EAI001 and EGFR<ce:sup loc="post">T790M</ce:sup> (Protein Data Bank [PDB] code 5D41). The key residues within the allosteric site of EAI001 are represented by sticks with carbon atoms. ANP, an analogue of ATP, is shown in the cocrystal structure. Left: structural overview; right: local details.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig.Â 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420300891/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig.Â 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">The cocrystal structure of BMS-066 and Tyk2. The right figure shows the detailed interactions between BMS-066 and Tyk2 (PDB code <ce:inter-ref id="intref0010" xlink:href="pdb:4WOV" xlink:type="simple">4WOV</ce:inter-ref>). Hydrogen bonds are displayed in green dashed lines, and other residues within the allosteric site are represented by sticks. Left: structural overview; right: local details. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig.Â 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420300891/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig.Â 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">The structural overview of Tyk2 in complex with BMS-986165 (PDB code <ce:inter-ref id="intref0015" xlink:href="pdb:6NZP" xlink:type="simple">6NZP</ce:inter-ref>). BMS-986165 occupies the non-classic âalanine pocketâ near a rare Ala671 in the JH2 domain of Tyk2. The key interactions including hydrogen bonds are shown as green dashed lines. The residues within the allosteric site are represented by sticks. Left: structural overview; right: local details. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig.Â 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420300891/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig.Â 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">X-ray crystal structure of ABL001 binds to the myristoyl pocket of Abl (PDB code <ce:inter-ref id="intref0020" xlink:href="pdb:5MO4" xlink:type="simple">5MO4</ce:inter-ref>). The hydrogen bond is shown as green dashed lines. The residues within the allosteric site are represented by sticks. Left: structural overview; right: local details. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig.Â 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523420300891/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig.Â 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">The orthosteric and allosteric pockets/sites in STAT3. The SH2 domain of STAT3 possesses three orthosteric binding sub-pockets (blue). The pY pocket consists of polar residues, such as Lys591, Glu594, Arg609, Ser611, Glu612, and Ser613. pYÂ + 1 pocket is composed of Thr620, Lys626, Gln635 and Ser636. pY-X pocket consists of Met586, Gly587, Phe588, Ile589, and Ser590. Three allosteric pockets/sites are shown in the crystal structure of STAT3 (PDB code 1BG1). Allosteric site 1 (red) is located in LD domain that consists of Leu533, Pro535, Val537, Tyr539, and Cys542. CCD domain possesses allosteric site 2 (Asp170 and Phe174, orange) and 3 (Asp171, Asn175, Gln202, and Met213, green). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig.Â 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523420300891/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig.Â 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">
                     <ce:inter-ref id="intref0025" xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>Chemical structures of allosteric inhibitors directly targeting STAT3 and PROTAC STAT3 degrader (SD-36).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig.Â 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523420300891/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>TableÂ 1</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="tspara0010" view="all">Allosteric inhibitors of the STAT3 signaling pathway.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">TableÂ 1</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Target</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Indication</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Remark</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EAI001</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR<sup loc="post">L858R/T790M</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR-mutant lung cancer [<cross-ref id="crosref0800" refid="bib58">58</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EAI045</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR<sup loc="post">L858R/T790M</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR-mutant lung cancer [<cross-ref id="crosref0805" refid="bib58">58</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JBJ-04-125-02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR<sup loc="post">L858R/T790M</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR-mutant lung cancer [<cross-ref id="crosref0810" refid="bib59">59</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3s</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR<sup loc="post">T790M/L858R</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR-mutant lung cancer [<cross-ref id="crosref0815" refid="bib60">60</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR<sup loc="post">T790M/L858R</sup>, EGFR<sup loc="post">WT</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR-mutant lung cancer [<cross-ref id="crosref0820" refid="bib61">61</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SSR128129E</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pancreatic cancer, breast cancer, lung cancer, colon cancer, myeloma, and rheumatoid arthritis [<cross-ref id="crosref0825" refid="bib66">66</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tyk2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting IL-23-induced STAT activation in kit225 human T cells [<cross-ref id="crosref0830" refid="bib75">75</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BMS-066</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tyk2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting IL-23-induced STAT activation in kit225 human T cells [<cross-ref id="crosref0835" refid="bib75">75</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tyk2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting IL-23/IFNÎ±-induced STAT activation in kit225 human T cells [<cross-ref id="crosref0840" refid="bib76">76</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BMS-986165</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tyk2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Psoriasis [<cross-ref id="crosref0845" refid="bib77">77</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">G5-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PTEN-deficient glioblastoma [<cross-ref id="crosref0850" refid="bib78">78</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">B6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast caner [<cross-ref id="crosref0855" refid="bib79">79</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">GNF-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Abl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CML and Ph<sup loc="post">+</sup>Â ALL [<cross-ref id="crosref0860" refid="bib83">83</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">GNF-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Abl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CML and Ph<sup loc="post">+</sup>Â ALL [<cross-ref id="crosref0865" refid="bib83">83</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ABL001</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Abl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CML and Ph<sup loc="post">+</sup>Â ALL [<cross-ref id="crosref0870" refid="bib84">84</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CML and Ph<sup loc="post">+</sup> ALL, clinical phase I (NCT03595917) [<cross-ref id="crosref0875" refid="bib85">85</cross-ref>,<cross-ref id="crosref0880" refid="bib86">86</cross-ref>]<br/></br>Advanced solid tumors, clinical phase I (NCT03292783)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BO1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Abl<sup loc="post">T315I</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Kinase activity assay [<cross-ref id="crosref0885" refid="bib87">87</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Abl<sup loc="post">T315I</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Kinase activity assay [<cross-ref id="crosref0890" refid="bib88">88</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13b</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Abl<sup loc="post">T315I</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Kinase activity assay [<cross-ref id="crosref0895" refid="bib88">88</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ANS</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Src</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Molecular dynamics assay [<cross-ref id="crosref0900" refid="bib90">90</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CYD0618</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3 LD domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ovarian cancer and breast cancer [<cross-ref id="crosref0905" refid="bib92">92</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MM-206</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3 CCD domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AML [<cross-ref id="crosref0910" refid="bib95">95</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C188</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3 CCD domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer [<cross-ref id="crosref0915" refid="bib95">95</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">K116</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3 CCD domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer and prostatic cancer [<cross-ref id="crosref0920" refid="bib98">98</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Allosteric inhibitors of the STAT3 signaling pathway</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420300891-e20b16126f982ca70c4fa540082fa369">
                  <ce:given-name>Junhong</ce:given-name>
                  <ce:surname>Qin</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420300891-e63b3ea51ccfeb11cf2e3beef8b08dec">
                  <ce:given-name>Xiaofei</ce:given-name>
                  <ce:surname>Shen</ce:surname>
                  <ce:cross-ref id="crosref0015" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0020" refid="cor1">
                     <ce:sup loc="post">â</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au3" author-id="S0223523420300891-62114f3fc3878a1659d44527f38ccf3b">
                  <ce:given-name>Jian</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0025" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420300891-37770d89d5c899add226e297e770bcb4">
                  <ce:given-name>Da</ce:given-name>
                  <ce:surname>Jia</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0035" refid="cor2">
                     <ce:sup loc="post">ââ</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420300891-198e0ede41db048953de768b78641603">
                  <ce:label>a</ce:label>
                  <ce:textfn>Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Paediatrics, West China Second University Hospital, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, 610041, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Key Laboratory of Birth Defects and Related Diseases of Women and Children</sa:organization>
                     <sa:organization>Department of Paediatrics</sa:organization>
                     <sa:organization>West China Second University Hospital</sa:organization>
                     <sa:organization>State Key Laboratory of Biotherapy</sa:organization>
                     <sa:organization>Sichuan University</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>610041</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Paediatrics, West China Second University Hospital, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, 610041, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420300891-2255fdd85c666cd3ee497920d12ee221">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200025, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Pathophysiology</sa:organization>
                     <sa:organization>Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education</sa:organization>
                     <sa:organization>Shanghai Jiao-Tong University School of Medicine</sa:organization>
                     <sa:city>Shanghai</sa:city>
                     <sa:postal-code>200025</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200025, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>â</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>ââ</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="30" month="12" year="2019"/></ce:date-received>
            <ce:date-revised day="4" month="2" year="2020"/></ce:date-revised>
            <ce:date-accepted day="4" month="2" year="2020"/></ce:date-accepted>
            <ce:abstract class="author" id="abs0010" xml:lang="en" view="all"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Over-expression and/or hyperactivation of signal transducer and activator of transcription 3 (STAT3) signaling are found in various human diseases, including cancer, autoimmune disorders, and inflammatory diseases. Therefore, STAT3 represents a highly promising therapeutic target for the treatment of these diseases. However, the traditional orthosteric inhibitors of STAT3 exhibit limited clinical efficacy, with low selectivity, numerous side effects, and emerging acquired resistance. Allosteric inhibitors targeting STAT3 or its upstream molecules have emerged as a promising approach to overcome these barriers. In this review, we summarize the recent advances in the development of these inhibitors as well as their applications.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420300891/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords class="keyword" id="kwrds0010" xml:lang="en" view="all">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>STAT3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Cancer</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Autoimmune/inflammatory diseases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Allosteric inhibitors</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:nomenclature id="nomen0010" view="all">
               <ce:section-title id="sectitle0030">Abbreviation table</ce:section-title>
               <ce:def-list id="dlist0010">
                  <ce:def-term id="d0010">
                     <ce:bold>Abl</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0010">
                     <ce:para id="p0025" view="all">Abelson murine leukemia viral oncogene homolog 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0015">
                     <ce:bold>AML</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0015">
                     <ce:para id="p0030" view="all">acute myeloid leukemia</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0020">
                     <ce:bold>ALL</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0020">
                     <ce:para id="p0035" view="all">acute lymphoblastic leukemia</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0025">
                     <ce:bold>Bcl-2</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0025">
                     <ce:para id="p0040" view="all">B-cell lymphoma-2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0030">
                     <ce:bold>Bcr</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0030">
                     <ce:para id="p0045" view="all">breakpoint cluster region gene</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0035">
                     <ce:bold>CCD</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0035">
                     <ce:para id="p0050" view="all">coiledâcoiled domain</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0040">
                     <ce:bold>CDK2</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0040">
                     <ce:para id="p0055" view="all">cyclin-dependent kinase 2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0045">
                     <ce:bold>CML</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0045">
                     <ce:para id="p0060" view="all">chronic myeloid leukemia</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0050">
                     <ce:bold>c-Myc</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0050">
                     <ce:para id="p0065" view="all">cellular myelocytomatosis viral oncogene homolog</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0055">
                     <ce:bold>COX-2</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0055">
                     <ce:para id="p0070" view="all">cyclooxygenase 2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0060">
                     <ce:bold>CXCR4</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0060">
                     <ce:para id="p0075" view="all">CXC chemokine receptor 4</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0065">
                     <ce:bold>DBD</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0065">
                     <ce:para id="p0080" view="all">DNA-binding domain</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0070">
                     <ce:bold>EGF</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0070">
                     <ce:para id="p0085" view="all">epidermal growth factor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0075">
                     <ce:bold>EGFR</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0075">
                     <ce:para id="p0090" view="all">epidermal growth factor receptor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0080">
                     <ce:bold>FDA</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0080">
                     <ce:para id="p0095" view="all">Food and Drug Administration</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0085">
                     <ce:bold>FERM</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0085">
                     <ce:para id="p0100" view="all">4.1/ezrin/radixin/moesin</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0090">
                     <ce:bold>FGF</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0090">
                     <ce:para id="p0105" view="all">fibroblast growth factor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0095">
                     <ce:bold>IBD</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0095">
                     <ce:para id="p0110" view="all">inflammatory bowel disease</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0100">
                     <ce:bold>IFN-Î³</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0100">
                     <ce:para id="p0115" view="all">interferon-Î³</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0105">
                     <ce:bold>IGF</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0105">
                     <ce:para id="p0120" view="all">insulin-like growth factor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0110">
                     <ce:bold>IL-6</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0110">
                     <ce:para id="p0125" view="all">interleukin 6</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0115">
                     <ce:bold>iNOS</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0115">
                     <ce:para id="p0130" view="all">inducible nitric oxide synthetase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0120">
                     <ce:bold>JAKs</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0120">
                     <ce:para id="p0135" view="all">Janus kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0125">
                     <ce:bold>JH1</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0125">
                     <ce:para id="p0140" view="all">Janus homology 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0130">
                     <ce:bold>LD</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0130">
                     <ce:para id="p0145" view="all">linker domain</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0135">
                     <ce:bold>MD</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0135">
                     <ce:para id="p0150" view="all">molecular dynamics</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0140">
                     <ce:bold>MMP-2</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0140">
                     <ce:para id="p0155" view="all">matrix metalloproteinase 2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0145">
                     <ce:bold>NH2 domain</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0145">
                     <ce:para id="p0160" view="all">amino-terminal (NH2) domain</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0150">
                     <ce:bold>NMR</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0150">
                     <ce:para id="p0165" view="all">nuclear magnetic resonance</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0155">
                     <ce:bold>PDB</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0155">
                     <ce:para id="p0170" view="all">Protein Data Bank</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0160">
                     <ce:bold>PDGF</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0160">
                     <ce:para id="p0175" view="all">platelet-derived growth factor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0165">
                     <ce:bold>PD-L1</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0165">
                     <ce:para id="p0180" view="all">programmed cell death-ligand 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0170">
                     <ce:bold>PIAS</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0170">
                     <ce:para id="p0185" view="all">protein inhibitor of activated STAT3</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0175">
                     <ce:bold>PROTAC</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0175">
                     <ce:para id="p0190" view="all">proteolysis targeting chimera</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0180">
                     <ce:bold>PTPs</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0180">
                     <ce:para id="p0195" view="all">protein tyrosine phosphatases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0185">
                     <ce:bold>RA</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0185">
                     <ce:para id="p0200" view="all">rheumatoid arthritis</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0190">
                     <ce:bold>Ras</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0190">
                     <ce:para id="p0205" view="all">rat sarcoma</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0195">
                     <ce:bold>RTKs</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0195">
                     <ce:para id="p0210" view="all">receptor tyrosine kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0200">
                     <ce:bold>SH2</ce:bold> domain</ce:def-term>
                  <ce:def-description id="defdis0200">
                     <ce:para id="p0215" view="all">Src homology 2 domain</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0205">
                     <ce:bold>SHP-1/2</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0205">
                     <ce:para id="p0220" view="all">Src homology domain-containing tyrosine phosphatases 1/2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0210">
                     <ce:bold>SOCS</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0210">
                     <ce:para id="p0225" view="all">suppressors of cytokine signaling</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0215">
                     <ce:bold>Src</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0215">
                     <ce:para id="p0230" view="all">sarcoma gene</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0220">
                     <ce:bold>STAT3</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0220">
                     <ce:para id="p0235" view="all">signal transducer and activator of transcription 3</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0225">
                     <ce:bold>TAD</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0225">
                     <ce:para id="p0240" view="all">transcriptional activation domain</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0230">
                     <ce:bold>Tyk2</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0230">
                     <ce:para id="p0245" view="all">tyrosine protein kinase 2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0235">
                     <ce:bold>VEGF</ce:bold>
                  </ce:def-term>
                  <ce:def-description id="defdis0235">
                     <ce:para id="p0250" view="all">vascular endothelial growth factor</ce:para>
                  </ce:def-description>
               </ce:def-list>
            </ce:nomenclature>
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0035">Introduction</ce:section-title>
                  <ce:para id="p0255" view="all">Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family, is a latent transcription factor that can transduce extracellular signals to the nucleus [<ce:cross-ref id="crosref0040" refid="bib1">1</ce:cross-ref>]. STAT3 is a multi-domain protein comprised of six functional domains, including the highly conserved amino-terminal (NH2) domain, the coiledâcoiled domain (CCD), the DNA-binding domain (DBD), the linker domain (LD), and the Src homology 2 (SH2) domain, as well as the specific transcriptional activation domain (TAD) [<ce:cross-ref id="crosref0045" refid="bib2">2</ce:cross-ref>]. STAT3 mediates responses to stimulation caused by growth factors and cytokines, as well as other intracellular and extracellular signals [<ce:cross-ref id="crosref0050" refid="bib3">3</ce:cross-ref>]. Once ligands, such as interleukin 6 (IL-6), IL-10, IL-11, interferon-Î³ (IFN-Î³), epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) bind to their cell surface receptors, several upstream kinases can be recruited and activated [<ce:cross-ref id="crosref0055" refid="bib2">2</ce:cross-ref>,<ce:cross-ref id="crosref0060" refid="bib3">3</ce:cross-ref>]. These kinases, including Janus kinases (JAKs), receptor tyrosine kinases (RTKs, such as epidermal growth factor receptor [EGFR]), and non-receptor tyrosine kinases (e.g. sarcoma gene [Src] and abelson murine leukemia viral oncogene homolog 1 [Abl]), then phosphorylate the Tyr705 residue of STAT3 located in its SH2 domain [<ce:cross-refs id="crosrefs0010" refid="bib3 bib4 bib5">3â5</ce:cross-refs>]. Phosphorylation of Tyr705 then promotes STAT3 dimerization via the binding of phosphorylated Tyr705 of one monomer to the SH2 domain of another [<ce:cross-refs id="crosrefs0015" refid="bib4 bib5 bib6 bib7">4â7</ce:cross-refs>]. Subsequently, the dimer translocates to the nucleus, binds to specific DNA-response elements, and induces the transcription and translation of target genes involved in many cellular processes, including cell proliferation (e.g. cellular myelocytomatosis viral oncogene homolog [c-Myc] and cyclin D1), apoptosis (such as B-cell lymphoma-2 [Bcl-2], Bcl-xL, and survivin), angiogenesis (like VEGF), metastasis (e.g. matrix metalloproteinase 2 [MMP-2] and MMP-9), and immune response (including cyclooxygenase 2 [COX-2], inducible nitric oxide synthetase [iNOS], programmed cell death-ligand 1 [PD-L1], and CXC chemokine receptor 4 [CXCR4]) [<ce:cross-refs id="crosrefs0020" refid="bib4 bib5 bib6 bib7 bib8">4â8</ce:cross-refs>] (<ce:cross-ref id="crosref0065" refid="fig1">Fig.Â 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0260" view="all">In addition to Tyr705, phosphorylation of Serine 727 located in the TAD of STAT3 further enhances STAT3 target gene transcription [<ce:cross-ref id="crosref0070" refid="bib9">9</ce:cross-ref>], and promotes the rat sarcoma (Ras)-mediated malignant transformation [<ce:cross-ref id="crosref0075" refid="bib10">10</ce:cross-ref>]. In contrast, the STAT3 signaling can be inactivated by several distinct mechanisms [<ce:cross-ref id="crosref0080" refid="bib11">11</ce:cross-ref>] (<ce:cross-ref id="crosref0085" refid="fig1">Fig.Â 1</ce:cross-ref>). For instance, protein tyrosine phosphatases (PTPs, such as Src homology domain-containing tyrosine phosphatases 1/2 [SHP-1/2]) inactivate the STAT3 pathway via de-phosphorylation of Tyr705 [<ce:cross-ref id="crosref0090" refid="bib12">12</ce:cross-ref>,<ce:cross-ref id="crosref0095" refid="bib13">13</ce:cross-ref>]. Suppressors of cytokine signaling (SOCS) interact with the JAK domains or intracellular regions of the RTKs [<ce:cross-ref id="crosref0100" refid="bib14">14</ce:cross-ref>,<ce:cross-ref id="crosref0105" refid="bib15">15</ce:cross-ref>]. Finally, protein inhibitor of activated STAT3 (PIAS) inhibits the binding of DNA to STAT3 [<ce:cross-ref id="crosref0110" refid="bib10">10</ce:cross-ref>,<ce:cross-ref id="crosref0115" refid="bib16">16</ce:cross-ref>].</ce:para>
                  <ce:para id="p0265" view="all">In normal cells, activation of STAT3 signaling is transient and controlled. In contrast, about 70% of human solid and hematological tumors harbor over-expressed and/or constitutively activated STAT3 [<ce:cross-ref id="crosref0120" refid="bib3">3</ce:cross-ref>,<ce:cross-ref id="crosref0125" refid="bib17">17</ce:cross-ref>]. Furthermore, the expression and activation levels of STAT3 are correlated with the malignancy and clinical prognosis of various tumors, including gastric cancer [<ce:cross-ref id="crosref0130" refid="bib18">18</ce:cross-ref>,<ce:cross-ref id="crosref0135" refid="bib19">19</ce:cross-ref>], liver cancer [<ce:cross-ref id="crosref0140" refid="bib20">20</ce:cross-ref>,<ce:cross-ref id="crosref0145" refid="bib21">21</ce:cross-ref>], colorectal cancer [<ce:cross-ref id="crosref0150" refid="bib22">22</ce:cross-ref>,<ce:cross-ref id="crosref0155" refid="bib23">23</ce:cross-ref>], breast cancer [<ce:cross-ref id="crosref0160" refid="bib24">24</ce:cross-ref>,<ce:cross-ref id="crosref0165" refid="bib25">25</ce:cross-ref>], and ovarian cancer [<ce:cross-ref id="crosref0170" refid="bib26">26</ce:cross-ref>,<ce:cross-ref id="crosref0175" refid="bib27">27</ce:cross-ref>]. More recently, activation of STAT3 has been identified as a critical mechanism of acquired drug resistance in the targeted drug therapies, as exemplified through RTKs inhibitors [<ce:cross-ref id="crosref0180" refid="bib28">28</ce:cross-ref>,<ce:cross-ref id="crosref0185" refid="bib29">29</ce:cross-ref>]. Hyperactive STAT3 in tumor microenvironments is also responsible for the tumor immune evasion through recruiting and activating of regulatory T (Treg) cells and tolerogenic dendritic cells [<ce:cross-ref id="crosref0190" refid="bib30">30</ce:cross-ref>], and up-regulating immunosuppressive factors, including PD1/PD-L1 [<ce:cross-ref id="crosref0195" refid="bib31">31</ce:cross-ref>] and COX2 [<ce:cross-ref id="crosref0200" refid="bib32">32</ce:cross-ref>]. Unlike normal cells, cancerous cells are more sensitive to loss of STAT3 function [<ce:cross-ref id="crosref0205" refid="bib33">33</ce:cross-ref>]. Given its key role in tumorigenesis and tumor development, the STAT3 signaling pathway represents an attractive drug target for cancer therapy [<ce:cross-refs id="crosrefs0025" refid="bib4 bib5 bib6">4â6</ce:cross-refs>,<ce:cross-ref id="crosref0210" refid="bib17">17</ce:cross-ref>]. In addition to cancer, constitutively activated STAT3 is also observed in patients with rheumatoid arthritis (RA) [<ce:cross-ref id="crosref0215" refid="bib34">34</ce:cross-ref>] and inflammatory bowel disease (IBD) [<ce:cross-ref id="crosref0220" refid="bib35">35</ce:cross-ref>]. STAT3 plays a pivotal role in the progress of these autoimmune and inflammatory diseases [<ce:cross-ref id="crosref0225" refid="bib36">36</ce:cross-ref>]. Hence, STAT3 is also a promising target for these immune-related diseases [<ce:cross-ref id="crosref0230" refid="bib37">37</ce:cross-ref>].</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0040">Orthosteric inhibitors <ce:italic>vs</ce:italic> allosteric inhibitors</ce:section-title>
                  <ce:para id="p0270" view="all">Small-molecule inhibitors of the STAT3 signaling pathway can target either the upstream cell surface receptors, kinases, or STAT3 itself through directly binding [<ce:cross-ref id="crosref0235" refid="bib17">17</ce:cross-ref>]. Traditionally, the ATP-binding pockets of kinases are one of the major targets of small-molecule inhibitors [<ce:cross-ref id="crosref0240" refid="bib38">38</ce:cross-ref>]. However, numerous kinases share a highly conserved ATP-binding pocket (an orthosteric pocket), which leads to undesired selectivity profiles and off-target effects [<ce:cross-ref id="crosref0245" refid="bib38">38</ce:cross-ref>,<ce:cross-ref id="crosref0250" refid="bib39">39</ce:cross-ref>]. The site mutations in the ATP-binding pocketÂ also result in the emergence of drug resistance [<ce:cross-ref id="crosref0255" refid="bib39">39</ce:cross-ref>]. Direct inhibitors of STAT3 often target the SH2 domain or the DBD domain. However, highly conservation of the SH2 domain in the STAT family, coupled with difficulties in targeting the SH2 domain-mediated protein-protein interaction, result in relatively limited selectivity and efficacy of STAT3-SH2 inhibitors [<ce:cross-ref id="crosref0260" refid="bib40">40</ce:cross-ref>]. In addition, the lack of high-throughput screening methods also greatly hinders the development of STAT3-DBD inhibitors [<ce:cross-ref id="crosref0265" refid="bib17">17</ce:cross-ref>]. So far, no small-molecule inhibitors of STAT3 have been approved by the Food and Drug Administration (FDA). In light of the critical role of STAT3 in the carcinogenesis and tumor progression, there remains a great interest in targeting STAT3 [<ce:cross-refs id="crosrefs0030" refid="bib4 bib5 bib6">4â6</ce:cross-refs>,<ce:cross-ref id="crosref0270" refid="bib17">17</ce:cross-ref>].</ce:para>
                  <ce:para id="p0275" view="all">While orthosteric inhibitors remain the leading focus for drug discovery, targeting of allosteric sites is gaining increasing attention [<ce:cross-ref id="crosref0275" refid="bib41">41</ce:cross-ref>]. Allostery or allosteric modulation is one of the inherent properties of biomacromolecules, including proteins [<ce:cross-ref id="crosref0280" refid="bib42">42</ce:cross-ref>]. Typical allosteric regulation is defined as a conformational change induced by perturbations at the allosteric sites via the binding of ligands (including proteins, DNA, RNA, ions, and small molecules), point mutations, and post-translational modifications [<ce:cross-ref id="crosref0285" refid="bib43">43</ce:cross-ref>,<ce:cross-ref id="crosref0290" refid="bib44">44</ce:cross-ref>]. The allosteric modulators-induced structural and/or dynamical alterations of biomacromolecules then cause changes in their activity and function, thereby exquisitely regulating multiple biological processes, including enzyme catalysis, gene transcription and translation, cellular proliferation and metabolism [<ce:cross-ref id="crosref0295" refid="bib42">42</ce:cross-ref>,<ce:cross-refs id="crosrefs0035" refid="bib44 bib45 bib46">44â46</ce:cross-refs>]. Targeting allosteric sites by small molecules presents multiple advantages, relative to orthosteric sites. First, allosteric sites are often topologically and spatially distinct from orthosteric sites. Thus, allosteric inhibitors can cooperatively function with orthosteric endogenous ligands or exogenous inhibitors [<ce:cross-ref id="crosref0300" refid="bib47">47</ce:cross-ref>]. Second, allosteric inhibitors have the potential to overcome drug resistance caused by gene mutations at the orthosteric sites [<ce:cross-ref id="crosref0305" refid="bib48">48</ce:cross-ref>]. Third, allosteric sites or pockets usually show a high structural diversity relative to orthosteric sites, resulting in potentially improved selectivity, lower toxicity, and better druggability [<ce:cross-ref id="crosref0310" refid="bib49">49</ce:cross-ref>,<ce:cross-ref id="crosref0315" refid="bib50">50</ce:cross-ref>]. Finally, allosteric regulation provides a strategy for targeting the âundruggableâ proteins, which often have high substrate binding affinity, shallow binding pockets, or large and flat protein-protein interaction interfaces [<ce:cross-refs id="crosrefs0040" refid="bib51 bib52 bib53">51â53</ce:cross-refs>]. Thus, harnessing and capitalizing on allosteric regulation represents a promising approach to overcome the current difficulties associated with the development of STAT3 inhibitors. In recent years, tremendous efforts have been made toward developing allosteric inhibitors targeting various members of the STAT3 signaling pathway.</ce:para>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0045">Allosteric inhibitors of cell surface receptors</ce:section-title>
                  <ce:para id="p0280" view="all">Cell surface receptors, including EGFR, FGFR, VEGFR, and gp130, mediate the activation of STAT3 by growth factors and cytokines [<ce:cross-ref id="crosref0320" refid="bib4">4</ce:cross-ref>]. Targeting these growth factor/cytokine receptors has been shown to be an effective strategy to inhibit aberrant STAT3 activation [<ce:cross-ref id="crosref0325" refid="bib17">17</ce:cross-ref>]. Most of current EGFR inhibitors, such as gefitinib, erlotinib, and afatinib, target the ATP-binding site of the kinases [<ce:cross-ref id="crosref0330" refid="bib54">54</ce:cross-ref>,<ce:cross-ref id="crosref0335" refid="bib55">55</ce:cross-ref>]. However, the emergence of drug resistance calls for therapeutic agents with alternative mechanisms of action. For example, T790M and C979S mutations in EGFR were reported to be the leading mechanism of resistance to traditional EGFR inhibitors [<ce:cross-ref id="crosref0340" refid="bib56">56</ce:cross-ref>,<ce:cross-ref id="crosref0345" refid="bib57">57</ce:cross-ref>]. Recently, Jia etÂ al. identified EAI001 (<ce:cross-ref id="crosref0350" refid="fig2">Fig.Â 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>) as an allosteric and non-ATP competitive inhibitor that targets the selected drug-resistant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> mutant, but not the wild-type protein [<ce:cross-ref id="crosref0355" refid="bib58">58</ce:cross-ref>]. Complex structure mapping reveals that the compound binds to an allosteric pocket that is formed by outward displacement of the C-helix in the inactive conformation of the kinase. Within this allosteric pocket, EAI001 forms hydrogen bonds with Asp855 in the DFG motif, and forms hydrophobic interactions between Leu777 and Phe856 (<ce:cross-ref id="crosref0360" refid="fig3">Fig.Â 3</ce:cross-ref>
                     <ce:float-anchor refid="fig3"/></ce:float-anchor>). Furthermore, EAI045 (<ce:cross-ref id="crosref0365" refid="fig2">Fig.Â 2</ce:cross-ref>), a synthesized analogue of EAI001, is active and selective for monomeric EGFR<ce:sup loc="post">T790M</ce:sup> with IC<ce:inf loc="post">50</ce:inf> values of 3Â nM. When combined with cetuximab, a monoclonal antibody that can block the dimerization of EGFR, EAI045 shows a significant inhibitory effect in a mouse model of EGFR<ce:sup loc="post">L858R/T790M</ce:sup>-drived lung cancer [<ce:cross-ref id="crosref0370" refid="bib48">48</ce:cross-ref>,<ce:cross-ref id="crosref0375" refid="bib58">58</ce:cross-ref>]. To etÂ al. identified another analogue of EAI001, JBJ-04-125-02 (<ce:cross-ref id="crosref0380" refid="fig2">Fig.Â 2</ce:cross-ref>), as a more potent allosteric inhibitor of the EGFR mutant (IC<ce:inf loc="post">50</ce:inf>Â =Â 0.26Â nM). JBJ-04-125-02, on its own, inhibits cell proliferation and cancer growth in a mouse model [<ce:cross-ref id="crosref0385" refid="bib59">59</ce:cross-ref>]. Altogether, these findings illustrate that targeting allosteric sites provides exciting opportunity for the development of inhibitors against mutant proteins.</ce:para>
                  <ce:para id="p0285" view="all">Carlino etÂ al. identified hexahydrocyclopenta[<ce:italic>c</ce:italic>]quinoline analogues as another class of allosteric inhibitors of EGFR. These small molecules target both EGFR and cyclin-dependent kinase 2 (CDK2). Remarkably, some derivatives, such as <ce:bold>3s</ce:bold> (<ce:cross-ref id="crosref0390" refid="fig2">Fig.Â 2</ce:cross-ref>), were selectively against the EGFR<ce:sup loc="post">T790M/L858R</ce:sup> mutant, but did not inactivate wild-type EGFR and CDK2 [<ce:cross-ref id="crosref0395" refid="bib60">60</ce:cross-ref>]. Using a docking method based on the mutant protein model of EGFR, Caporuscio etÂ al. identified another class of allosteric inhibitors, such as compound <ce:bold>8</ce:bold> (<ce:cross-ref id="crosref0400" refid="fig2">Fig.Â 2</ce:cross-ref>), for both wild-type and T790M/L858R mutant EGFR [<ce:cross-ref id="crosref0405" refid="bib61">61</ce:cross-ref>].</ce:para>
                  <ce:para id="p0290" view="all">The FGFR/VEGFR signaling is crucial for cancer angiogenesis [<ce:cross-ref id="crosref0410" refid="bib62">62</ce:cross-ref>]. The FDA approved FGFR inhibitor, ponatinib [<ce:cross-ref id="crosref0415" refid="bib63">63</ce:cross-ref>], and VEGFR inhibitor, sorafenib [<ce:cross-ref id="crosref0420" refid="bib64">64</ce:cross-ref>], have been shown to reduce STAT3 activation <ce:italic>inÂ vitro</ce:italic> and <ce:italic>inÂ vivo</ce:italic>. These drugs prolong the survival of cancer patients, but their effectiveness is restricted by refractoriness, escape, and increased metastasis [<ce:cross-ref id="crosref0425" refid="bib65">65</ce:cross-ref>]. Combinatorial administration with allosteric inhibitors may help to overcome these challenges. Recently, a novel FGFR allosteric inhibitor, SSR128129E (<ce:cross-ref id="crosref0430" refid="fig2">Fig.Â 2</ce:cross-ref>), was found to block tumor growth and metastasis (including pancreatic cancer, breast cancer, lung cancer, colon cancer, and myeloma), as well as FGF/VEGF-mediated angiogenesis in both tumor and arthritis models [<ce:cross-ref id="crosref0435" refid="bib66">66</ce:cross-ref>].</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0050">Allosteric kinases inhibitors</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0055">Allosteric JAKs inhibitors</ce:section-title>
                     <ce:para id="p0295" view="all">A variety of tyrosine kinases, such as JAKs, Src, and Abl, can bind to the SH2 domain of STAT3, and subsequently promote phosphorylation of STAT3 at Tyr705 [<ce:cross-refs id="crosrefs0045" refid="bib3 bib4 bib5">3â5</ce:cross-refs>]. So far, the development of traditional orthosteric inhibitors has focused on targeting JAK and Src kinases. For example, the orthosteric pan-JAK inhibitor tofacitinib and Src inhibitor bosutinib have been approved for treatment of autoimmune diseases [<ce:cross-ref id="crosref0440" refid="bib67">67</ce:cross-ref>] and chronic myeloid leukemia (CML) [<ce:cross-ref id="crosref0445" refid="bib68">68</ce:cross-ref>], respectively. JAK inhibitors (such as ruxolitinib, momelotinib, and upadacitinib) and Src inhibitors (including dasatinib and saracatinib) are undergoing a number of clinical trials for inflammatory diseases and multiple cancers [<ce:cross-refs id="crosrefs0050" refid="bib69 bib70 bib71">69â71</ce:cross-refs>]. However, off-target toxicity and increased infection often limit the applications of these tyrosine kinases inhibitors. Recently, several allosteric tyrosine kinase inhibitors have been developed, which may help the treatment of related diseases.</ce:para>
                     <ce:para id="p0300" view="all">The JAKs family contains four members, including JAK1, JAK2, JAK3, and tyrosine protein kinase 2(Tyk2) [<ce:cross-ref id="crosref0450" refid="bib72">72</ce:cross-ref>]. Among them, Tyk2 mediates the signaling transduction in response to several cytokines, including IL-12, IL-23, and type I interferon, and thus represents a promising therapeutic target for treating various autoimmune diseases [<ce:cross-ref id="crosref0455" refid="bib73">73</ce:cross-ref>]. JAK proteins contain four domains, including a 4.1/ezrin/radixin/moesin (FERM) domain, an SH2 domain, a Janus Homology 1 (JH1) domain (the kinase domain), and a pseudokinase (JH2) domain [<ce:cross-ref id="crosref0460" refid="bib74">74</ce:cross-ref>]. Orthosteric Tyk2 inhibitors usually target the ATP-binding site of the JH1 domain and inhibit the catalytic activity. However, due to the high homology between the active sites in the catalytic domain of JAK kinases, inhibitors targeting other domains have aroused great interest, especially for the JH2 domain. So far, two classes of compounds have been identified that targeting the pseudokinase domain (JH2) of TYK2, which in turn suppresses cytokine-mediated receptor activation of the catalytic (JH1) domain. First, Tokarski and colleagues identified a class of small molecules as a Tyk2 inhibitor (BMS-066 and compound <ce:bold>1</ce:bold>, <ce:cross-ref id="crosref0465" refid="fig2">Fig.Â 2</ce:cross-ref>) using a chemogenomics approach. Crystallization study shows that BMS-066 can sit in the deep cleft between the N- and C-terminal lobes of the pseudokinase domain of Tyk2, with the tricyclic ring system of BMS-066 occupying a site analogous to the ATP-binding site in catalytic kinases [<ce:cross-ref id="crosref0470" refid="bib75">75</ce:cross-ref>]. Furthermore, BMS-066 forms hydrogen bonds with Val690 and Leu595, and forms hydrophobic interactions between Val640, Pro694, Arg738, and Leu741 (<ce:cross-ref id="crosref0475" refid="fig4">Fig.Â 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>). Additionally, Moslin etÂ al. identified imidazo[1,2-<ce:italic>b</ce:italic>]pyridazine (IZP) compounds as another class of selective TYK2 inhibitor. IZP class compounds, such as compound <ce:bold>18</ce:bold> (<ce:cross-ref id="crosref0480" refid="fig2">Fig.Â 2</ce:cross-ref>), bind to the same pocket of the JH2 domain as BMS-066 [<ce:cross-ref id="crosref0485" refid="bib76">76</ce:cross-ref>]. The two classes of allosteric inhibitors, by targeting the less-conserved JH2 domain of Tyk2, display higher selectivity than traditional orthosteric inhibitors.</ce:para>
                     <ce:para id="p0305" view="all">In 2019, Wrobleski and colleagues reported a novel small molecule BMS-986165 (<ce:cross-ref id="crosref0490" refid="fig2">Fig.Â 2</ce:cross-ref>) as a high affinity JH2 ligand and potent allosteric inhibitor of Tyk2. Interestingly BMS-986165 occupies the non-classic âalanine pocketâ near a rare Ala671 in the JH2 domain of Tyk2 (<ce:cross-ref id="crosref0495" refid="fig5">Fig.Â 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>), unique from previously reported JAKs inhibitors. The binding of BMS-986165 to this atypical âalanine pocketâ endows BMS-986165 with unprecedented JAK isoform and kinome selectivity. In the IL-23 induced psoriasis-like acanthosis mouse model, BMS-986165 exhibited potent anti-inflammatory activity with excellent pharmacokinetic properties. Furthermore, BMS-986165 shows potent therapeutic effects on several murine models of autoimmune diseases, including lupus nephritis and IBD [<ce:cross-ref id="crosref0500" refid="bib77">77</ce:cross-ref>].</ce:para>
                     <ce:para id="p0310" view="all">In addition to Tyk2, several allosteric inhibitors have also been developed for other tyrosine kinases in recent years. For instance, G5-7 (1-piperidinecarboxylic acid, 4-oxo-3,5-bis(phenylmethylene)-ethyl esters, <ce:cross-ref id="crosref0505" refid="fig2">Fig.Â 2</ce:cross-ref>) was identified in a cell-based phenotypic screening assay to selectively inhibit JAK2-mediated activation of EGFR and STAT3. Mechanistically, G5-7 could directly bind to JAK2 through its FERM domain and allosterically inhibit the kinase activity of JAK2 on EGFR and STAT3 [<ce:cross-ref id="crosref0510" refid="bib78">78</ce:cross-ref>]. Shan etÂ al. identified 3-deoxy-2Î²,16-dihydroxynagilactone E (B6, <ce:cross-ref id="crosref0515" refid="fig2">Fig.Â 2</ce:cross-ref>), a natural compound from <ce:italic>Podocarpus nagi</ce:italic>, as a potent inhibitor of STAT3 signaling with an IC<ce:inf loc="post">50</ce:inf> of 0.2Â Î¼M [<ce:cross-ref id="crosref0520" refid="bib79">79</ce:cross-ref>]. Cellular thermal shift assay further showed that B6 directly interacted with the non-catalytic domain of JAK2. However, the exact binding site of B6 in JAK2 has not yet been identified.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0060">Allosteric Abl inhibitors</ce:section-title>
                     <ce:para id="p0315" view="all">Abl is a non-receptor tyrosine kinase that is involved in multiple intracellular signaling pathways, including STAT3 [<ce:cross-ref id="crosref0525" refid="bib80">80</ce:cross-ref>]. In general, a reciprocal chromosomal translocation between breakpoint cluster region gene (Bcr) and Abl causes the production of Bcr-Abl fusion protein with deregulated tyrosine kinase activity, which is responsible for different forms of human leukemia, such as chronic myelogenous leukemia [<ce:cross-ref id="crosref0530" refid="bib81">81</ce:cross-ref>]. Although several Bcr-Abl inhibitors, such as imatinib, have been used for the treatment of leukemia, allosteric inhibitors have the potential to overcome the emerging drug resistance [<ce:cross-ref id="crosref0535" refid="bib82">82</ce:cross-ref>].</ce:para>
                     <ce:para id="p0320" view="all">In 2006, Gray and colleagues identified 4,6-pyrimidine class compounds, such as GNF-1 and GNF-2 (<ce:cross-ref id="crosref0540" refid="fig2">Fig.Â 2</ce:cross-ref>) as novel allosteric Bcr-Abl inhibitors. GNF-2 binds to the myristoyl pocket located near the C-terminus of Abl kinase domain, which alters the conformational dynamics of the ATP-binding site of Abl [<ce:cross-ref id="crosref0545" refid="bib83">83</ce:cross-ref>]. ABL001 (asciminib, <ce:cross-ref id="crosref0550" refid="fig2">Fig.Â 2</ce:cross-ref>), another potent and selective allosteric Abl inhibitor, also binds to the myristoyl pocket of Abl via forming a hydrogen bond with Ala356 (<ce:cross-ref id="crosref0555" refid="fig6">Fig.Â 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>), and induces the inactive conformation of the kinase [<ce:cross-ref id="crosref0560" refid="bib84">84</ce:cross-ref>]. These allosteric Abl inhibitors show a potent anti-proliferative activity toward Bcr-Abl-transformed cells <ce:italic>inÂ vitro</ce:italic> and <ce:italic>inÂ vivo</ce:italic>. Currently, ABL001 is in various stages of clinical trials, including recurrent CML [<ce:cross-ref id="crosref0565" refid="bib85">85</ce:cross-ref>] and Philadelphia chromosome-positive (Ph<ce:sup loc="post">+</ce:sup>) acute lymphoblastic leukemia (ALL) [<ce:cross-ref id="crosref0570" refid="bib86">86</ce:cross-ref>]. Furthermore, several compounds, such as BO1 (<ce:cross-ref id="crosref0575" refid="fig2">Fig.Â 2</ce:cross-ref>) [<ce:cross-ref id="crosref0580" refid="bib87">87</ce:cross-ref>] and a series of pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine compounds (like <ce:bold>13a</ce:bold> and <ce:bold>13b</ce:bold>, <ce:cross-ref id="crosref0585" refid="fig2">Fig.Â 2</ce:cross-ref>) [<ce:cross-ref id="crosref0590" refid="bib88">88</ce:cross-ref>], inhibited the activity of Abl<ce:sup loc="post">T315I</ce:sup> in an ATP-independent manner.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0065">Allosteric Src inhibitors</ce:section-title>
                     <ce:para id="p0325" view="all">Deregulated activation of Src kinases causes uncontrolled growth and metastasis of tumor cells [<ce:cross-ref id="crosref0595" refid="bib89">89</ce:cross-ref>]. Using molecular dynamics (MD) simulation, Shukla etÂ al. identified several potential allosteric sites in c-Src kinase. The simulation shows that two intermediate states (I1 and I2) exist along the activation pathway of c-Src. Interestingly, a previously reported CDK2 inhibitor, 8-anilino-1-naphthalene sulphonate (ANS, <ce:cross-ref id="crosref0600" refid="fig2">Fig.Â 2</ce:cross-ref>), binds to the I2 state of c-Src, thus tabilizing its partially active intermediate state and allosterically inhibiting c-Src [<ce:cross-ref id="crosref0605" refid="bib90">90</ce:cross-ref>].</ce:para>
                     <ce:para id="p0330" view="all">Although the above-mentioned allosteric kinase inhibitors possess excellent selectivity and clinical potencies, they target more than one member of the STAT family and could cause off-target effects [<ce:cross-ref id="crosref0610" refid="bib17">17</ce:cross-ref>,<ce:cross-ref id="crosref0615" refid="bib69">69</ce:cross-ref>]. Furthermore, since several carcinogenic signaling pathways converge on STAT3, targeting one or a few kinases is unlikely to be sufficient for inhibition of STAT3 activation [<ce:cross-ref id="crosref0620" refid="bib91">91</ce:cross-ref>]. Thus, directly targeting STAT3 protein represents another important strategy for the development of allosteric STAT3 inhibitors [<ce:cross-ref id="crosref0625" refid="bib17">17</ce:cross-ref>,<ce:cross-ref id="crosref0630" refid="bib91">91</ce:cross-ref>].</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:label>5</ce:label>
                  <ce:section-title id="sectitle0070">Direct and allosteric inhibitors of STAT3</ce:section-title>
                  <ce:para id="p0335" view="all">So far, the majority of STAT3 small-molecule inhibitors target to the phosphotyrosine binding site within the SH2 domain (orthosteric pocket, <ce:cross-ref id="crosref0635" refid="fig7">Fig.Â 7</ce:cross-ref>
                     <ce:float-anchor refid="fig7"/></ce:float-anchor>) or the DNA-binding site within the DBD. These binding sites are highly conserved among the STAT family members, which could potentially explain many problems with the corresponding inhibitors, such as lower selectivity, poor pharmacokinetic properties, and side effects in preclinical or clinical trials [<ce:cross-ref id="crosref0640" refid="bib17">17</ce:cross-ref>]. To overcome these problems, there has been a growing interest in targeting the specific allosteric sites or pockets in LD, CCD, or other domains.</ce:para>
                  <ce:para id="p0340" view="all">Namanja etÂ al. found an inter-domain allosteric communication in STAT3 protein using nuclear magnetic resonance (NMR). Interaction between the tyrosine phosphorylated peptide (pY-peptide) and the SH2 domain also alter the structure and dynamics of the LD and DBD domains of STAT3 protein. Consistently, a point mutation (I568F) in the LD domain, identified in a patient with autosomal-dominant hyper IgE syndrome, reduces the binding affinity of SH2 domain to the pY-peptide [<ce:cross-ref id="crosref0645" refid="bib92">92</ce:cross-ref>]. More recently, we demonstrated that a thiazole-derived oridonin analogue, CYD0618 (<ce:cross-ref id="crosref0650" refid="fig8">Fig.Â 8</ce:cross-ref>
                     <ce:float-anchor refid="fig8"/></ce:float-anchor>), covalently binds to Cys542 in the LD domain of STAT3 and specifically inhibits its phosphorylation and function. Despite binding to the LD domain, CYD0618 reduces STAT3 binding to the pY-peptide via an allosteric mechanism. Furthermore, <ce:italic>inÂ vitro</ce:italic> and <ce:italic>inÂ vivo</ce:italic> data showed that CYD0618 exhibited a potent anti-cancer effect in cancer cells that harbor constitutive STAT3 activation [<ce:cross-ref id="crosref0655" refid="bib93">93</ce:cross-ref>]. In agreement with our study, S-glutathionylation at Cys542 was found to impair JAK2-induced Tyr705 phosphorylation of STAT3 [<ce:cross-ref id="crosref0660" refid="bib94">94</ce:cross-ref>]. Taken together, these findings suggest that Cys542 in the LD domain and nearby regions constitute a new allosteric site (allosteric site <ce:bold>1,</ce:bold> 
                     <ce:cross-ref id="crosref0665" refid="fig7">Fig.Â 7</ce:cross-ref>) for the selective inhibition of STAT3.</ce:para>
                  <ce:para id="p0345" view="all">In addition to the LD domain, other domains can also function as binding sites for small molecules to allosterically regulate the activity of STAT3. Naphthalene sulfonamide MM-206 (<ce:cross-ref id="crosref0670" refid="fig8">Fig.Â 8</ce:cross-ref>) and its analogue, C188 (<ce:cross-ref id="crosref0675" refid="fig8">Fig.Â 8</ce:cross-ref>), directly bind to Phe174 in the CCD of STAT3 (allosteric site <ce:bold>2</ce:bold>, <ce:cross-ref id="crosref0680" refid="fig7">Fig.Â 7</ce:cross-ref>), and inhibit the association between STAT3 and pY-peptide [<ce:cross-ref id="crosref0685" refid="bib95">95</ce:cross-ref>]. MM-206 exhibits a potent anti-cancer effect in a xenograft model of acute myeloid leukemia (AML) through inhibition of STAT3 phosphorylation, suggesting that the CCD is another critical region for the development of allosteric STAT3 inhibitors [<ce:cross-ref id="crosref0690" refid="bib95">95</ce:cross-ref>].</ce:para>
                  <ce:para id="p0350" view="all">Traditionally, the discovery of allosteric inhibitors is often serendipitous, owing to the complexity of allosteric regulation [<ce:cross-ref id="crosref0695" refid="bib96">96</ce:cross-ref>]. Recently, advances in structural biology of allosterically-regulated proteins and the understanding of the allosteric mechanisms have greatly contributed to the development of allosteric inhibitors using high-throughput virtual screens [<ce:cross-ref id="crosref0700" refid="bib97">97</ce:cross-ref>]. In 2018, we developed a free and high-throughput platform to automatically identify the allosteric sites for a particular protein as well as its allosteric modulators, named as AlloFinder [<ce:cross-ref id="crosref0705" refid="bib98">98</ce:cross-ref>]. Using this platform, we have identified five potential allosteric sites on the surface of STAT3. Among them, site 5 located in the CCD of STAT3 was further selected for the screening of potential inhibitors, and subsequently a new compound (K116, <ce:cross-ref id="crosref0710" refid="fig8">Fig.Â 8</ce:cross-ref>) was identified to inhibit the binding between STAT3 and the pY-peptide with IC<ce:inf loc="post">50</ce:inf> value of 7.99Â Î¼M [<ce:cross-ref id="crosref0715" refid="bib98">98</ce:cross-ref>]. Molecular docking assay showed that K116 forms hydrophobic effects with Asp171, Gln202, and Met213 as well as a hydrogen bond with Asn175 (allosteric site <ce:bold>3</ce:bold>, <ce:cross-ref id="crosref0720" refid="fig7">Fig.Â 7</ce:cross-ref>) in STAT3. In addition to AlloFinder, other computational approaches, such as Allosite, STRESS, and CovCys, are also useful for the discovery of allosteric drugs [<ce:cross-ref id="crosref0725" refid="bib99">99</ce:cross-ref>].</ce:para>
               </ce:section>
               <ce:section id="sec6" role="conclusion" view="all">
                  <ce:label>6</ce:label>
                  <ce:section-title id="sectitle0075">Conclusions and prospects</ce:section-title>
                  <ce:para id="p0355" view="all">Over-expression or hyperactivation of STAT3 are observed in many types of human solid and hematological tumors, and the STAT3 signaling pathway is critical for tumorigenesis and tumor progression [<ce:cross-ref id="crosref0730" refid="bib5">5</ce:cross-ref>,<ce:cross-ref id="crosref0735" refid="bib7">7</ce:cross-ref>]. Similarly, dysregulation of STAT3 signaling also contributes to the development of several autoimmune and inflammatory diseases, including RA, IBD, and psoriasis [<ce:cross-refs id="crosrefs0055" refid="bib34 bib35 bib36">34â36</ce:cross-refs>]. STAT3 is thus regarded as an attractive therapeutic target in both cancer and immune system diseases. Despite extensive efforts, the development of effective therapy targeting the STAT3 signaling remains very challenging as orthosteric inhibitors have problems such as limited therapeutic efficacy, lower selectivity, and high rates of side effects. Allosteric inhibitors represent an exciting direction as they may have higher selectivity, fewer adverse effects, and lower toxicity. Recently, several upstream kinases and directly STAT3 allosteric inhibitors have been characterized, and showed great potentials in the treatment of cancers and autoimmune diseases in pre-clinical and clinical studies (<ce:cross-ref id="crosref0740" refid="tbl1">TableÂ 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl1"/></ce:float-anchor>). Furthermore, inhibition of STAT3 pathway can enhance the aspects of cancer immunity, which thus provide a rationale of combination of STAT3 pathway inhibitors and immune checkpoint inhibitors that may lead to synergistic efficacy [<ce:cross-ref id="crosref0745" refid="bib100">100</ce:cross-ref>]. However, early phase clinical study of combination of EGFR orthosteric inhibitor gefitinib with durvalumab (PD-L1 inhibitor) was associated with liver injury [<ce:cross-ref id="crosref0750" refid="bib101">101</ce:cross-ref>]. Therefore, optimizing dosing regimens, minimizing treatment related toxicities, and selecting appropriate biomarkers and endpoints should be considered carefully in the clinical development of combinations of STAT3 allosteric inhibitors and immunotherapy.</ce:para>
                  <ce:para id="p0360" view="all">Although with a brilliant future, the development of STAT3 allosteric inhibitors is also facing some great challenge. First, the majority of allosteric inhibitors are hydrophobic compounds with lower aqueous solubility and bioavailability [<ce:cross-ref id="crosref0755" refid="bib102">102</ce:cross-ref>]. Medicinal chemistry optimizations are needed for further improvement of the allosteric inhibitors. Second, successful rate of allosteric drug using <ce:italic>in silico</ce:italic> approaches remains low, despite of the recent improvement [<ce:cross-ref id="crosref0760" refid="bib97">97</ce:cross-ref>,<ce:cross-ref id="crosref0765" refid="bib99">99</ce:cross-ref>]. Last but not the least, mutations of allosteric sites could endow allosteric inhibitors with acquired resistance [<ce:cross-ref id="crosref0770" refid="bib103">103</ce:cross-ref>]. Furthermore, the dimerization and nuclear translocation of STAT3 is independent of Tyr705 phosphorylation [<ce:cross-ref id="crosref0775" refid="bib104">104</ce:cross-ref>,<ce:cross-ref id="crosref0780" refid="bib105">105</ce:cross-ref>]. In addition, unphosphorylated STAT3 also shows transcriptional activity [<ce:cross-ref id="crosref0785" refid="bib106">106</ce:cross-ref>]. Therefore, inhibiting STAT3 phosphorylation and/or dimerization with small-molecule inhibitors is not sufficient to completely block the transcriptional activity of STAT3.</ce:para>
                  <ce:para id="p0365" view="all">Very recently, Wang and colleagues developed a completely new approach to inhibit the STAT3 signaling using the proteolysis targeting chimera (PROTAC) technology [<ce:cross-ref id="crosref0790" refid="bib107">107</ce:cross-ref>]. They discovered that the small molecule SD-36 (<ce:cross-ref id="crosref0795" refid="fig8">Fig.Â 8</ce:cross-ref>) functioned as a selective degrader of STAT3. SD-36 contains two functional groups: a small-molecule binder of the STAT3 SH2 domain (SI-109), and a ligand for cereblon (CRBN) E3 ligase (lenalidomide). Upon binding to the SH2 domain of STAT3 via SI-109, CRBN is recruited, which in turn recruits an E2 enzyme to promote the ubiquitination of STAT3. The ubiquitinated STAT3 is then targeted for proteasome degradation. SD-36 displays a potent inhibitory effect with minimal toxicities in both cell lines and xenograft mouse models. The advantages of PROTAC degrader of STAT3, such as much more potent and higher selectivity, may overcome the limited clinical efficacy, side effects and toxicity raised by STAT3 orthosteric and/or allosteric inhibitors. In summary, the development of effective inhibitors for the STAT3 signaling pathway is still an exciting and evolving field as these small-molecule compounds have great therapeutic potentials for human cancer and other STAT3-driven diseases.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0080">Declaration of competing interest</ce:section-title>
               <ce:para id="p0370" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0085">Acknowledgment</ce:section-title>
               <ce:para id="p0375" view="all">This work was supported by <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100012166" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Key Research and Development Program of China</ce:grant-sponsor> Grant <ce:grant-number refid="gs1">2018YFC1005004</ce:grant-number>; <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Natural Science Foundation of China (NSFC)</ce:grant-sponsor> Grants <ce:grant-number refid="gs2">91854121</ce:grant-number>, <ce:grant-number refid="gs2">31871429</ce:grant-number>, and <ce:grant-number refid="gs2">31671477</ce:grant-number>; West China Second University Hospital of <ce:grant-sponsor id="gs4" sponsor-id="https://doi.org/10.13039/501100004912" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Sichuan University</ce:grant-sponsor> (Xin-ya fund); and <ce:grant-sponsor id="gs6" sponsor-id="https://doi.org/10.13039/501100004829" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Department of Science and Technology of Sichuan Province</ce:grant-sponsor> Grants <ce:grant-number refid="gs6">2018RZ0128</ce:grant-number> and <ce:grant-number refid="gs6">2018GZ0043</ce:grant-number>.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0090">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revisiting STAT3 signalling in cancer: new and unexpected biological functions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>736</sb:first-page>
                              <sb:last-page>746</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">H. Yu, H. Lee, A. Herrmann, R. Buettner, R. Jove, Revisiting STAT3 signalling in cancer: new and unexpected biological functions, Nat Rev Cancer. 28 (2014) 736-746.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Aigner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Just</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Stoiber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 isoforms: alternative fates in cancer?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>27</sb:first-page>
                              <sb:last-page>34</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">P. Aigner, V. Just, D. Stoiber, STAT3 isoforms: Alternative fates in cancer? Cytokine 118 (2019) 27-34.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhuang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of STAT signaling by acetylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1924</sb:first-page>
                              <sb:last-page>1931</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">S. Zhuang, Regulation of STAT signaling by acetylation, Cell Signal. 25 (2013) 1924â1931.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Debnath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6645</sb:first-page>
                              <sb:last-page>6668</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">B. Debnath, S. Xu, N. Neamati, Small molecule inhibitors of signal transducer and activator of transcription 3, J. Med. Chem. 55 (2012) 6645â6668.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>OâKeefe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Grandis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>234</sb:first-page>
                              <sb:last-page>248</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">D.E. Johnson, R.A. OâKeefe, J.R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat Rev Clin Oncol. 15 (2018) 234-248.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Laudisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cherubini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Monteleone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Stolfi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 interactors as potential therapeutic targets for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1787</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">F. Laudisi, F. Cherubini, G. Monteleone, C. Stolfi, STAT3 interactors as potential therapeutic targets for cancer treatment, Int J Mol Sci. 19 (2018) 1787.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multiple regulation pathways and pivotal biological functions of STAT3 in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>17663</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">J. Yuan, F. Zhang, R. Niu, Multiple regulation pathways and pivotal biological functions of STAT3 in cancer, Sci Rep. 5 (2015) 17663.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Banerjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Resat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of STAT3 in breast cancer cells: a review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2570</sb:first-page>
                              <sb:last-page>2578</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">K. Banerjee, H. Resat, Constitutive activation of STAT3 in breast cancer cells: A review, Int J Cancer. 138 (2016) 2570-2578.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Avalle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Camporeale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Camperi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Poli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 in cancer: a double edged sword</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>42</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">L. Avalle, A. Camporeale, A. Camperi, V. Poli, STAT3 in cancer: A double edged sword, Cytokine 98 (2017) 42-50.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Gough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Corlett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Schlessinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wegrzyn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Larner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mitochondrial Stat3 supports Ras-dependent oncogenic transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>324</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1713</sb:first-page>
                              <sb:last-page>1716</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">D.J. Gough, A. Corlett, K. Schlessinger, J. Wegrzyn, A.C. Larner, D.E. Levy, Mitochondrial Stat3 supports Ras-dependent oncogenic transformation, Science 324 (2009) 1713-1716.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Negative regulators of STAT3 signaling pathway in cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Manag. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4957</sb:first-page>
                              <sb:last-page>4969</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">M. Wu, D. Song, H. Li, Y. Yang, X. Ma, S. Deng, C. Ren, X. Shu, Negative regulators of STAT3 signaling pathway in cancers, Cancer Manag Res. 11 (2019) 4957-4969.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Lazo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>McQueeney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Burnett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wipf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Sharlow</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule targeting of PTPs in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biochem. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>96</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>171</sb:first-page>
                              <sb:last-page>181</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">J.S. Lazo, K.E. McQueeney, J.C. Burnett, P. Wipf, E.R. Sharlow, Small molecule targeting of PTPs in cancer, Int J Biochem Cell Biol. 96 (2018) 171-181.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.D.</ce:given-name>
                                 <ce:surname>Morales</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.S.</ce:given-name>
                                 <ce:surname>Jang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein tyrosine phosphatases as potential regulators of STAT3 signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>E2708</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">M. Kim, L.D. Morales, I.S. Jang, Y.Y. Cho, D.J. Kim, Protein tyrosine phosphatases as potential regulators of STAT3 signaling, Int J Mol Sci. 19 (2018) E2708.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Krebs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Hilton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SOCS proteins: negative regulators of cytokine signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Stem Cell.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>378</sb:first-page>
                              <sb:last-page>387</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">D.L. Krebs, D.J. Hilton, SOCS proteins: negative regulators of cytokine signaling, Stem Cells. 19 (2001) 378-387.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Croker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Nicholson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SOCS regulation of the JAK/STAT signalling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Semin. Cell Dev. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>414</sb:first-page>
                              <sb:last-page>422</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">B.A. Croker, H. Kiu, S.E. Nicholson, SOCS regulation of the JAK/STAT signalling pathway, Semin Cell Dev Biol. 19 (2008) 414-422.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Matsuura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>99</sb:first-page>
                              <sb:last-page>104</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">J. Long, G. Wang, I. Matsuura, D. He, F. Liu, Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3), Proc Natl Acad Sci USA. 101 (2004) 99-104.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Furtek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Backos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Matheson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Reigan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strategies and approaches of targeting STAT3 for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>308</sb:first-page>
                              <sb:last-page>318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">S.L. Furtek, D.S. Backos, C.J. Matheson, P. Reigan, Strategies and approaches of targeting STAT3 for cancer treatment, ACS Chem. Biol. 11 (2016) 308â318.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Cha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Ahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Kang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.I.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Ko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Hwang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Rim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 expression in gastric cancer indicates a poor prognosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Gastroenterol. Hepatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>646</sb:first-page>
                              <sb:last-page>651</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">D.Y. Kim, S.T. Cha, D.H. Ahn, H.Y. Kang, C.I. Kwon, K.H. Ko, S.G. Hwang, P.W. Park, K.S. Rim, S.P. Hong, STAT3 expression in gastric cancer indicates a poor prognosis, J Gastroenterol Hepatol. 24 (2009) 646â651.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Mol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>90</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1037</sb:first-page>
                              <sb:last-page>1046</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">H. Xiong, W. Du, J.L. Wang, Y.C. Wang, J.T. Tang, J. Hong, J.Y. Fang, Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer, J Mol Med. 90 (2012) 1037â1046.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.F.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Yeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Chai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Chunag</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Sheen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.T.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Clin. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>642</sb:first-page>
                              <sb:last-page>648</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">S.F. Yang, S.N. Wang, C.F. Wu, Y.T. Yeh, C.Y. Chai, S.C. Chunag, M.C. Sheen, K.T. Lee, Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma, J Clin Pathol. 60 (2007) 642â648.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.S.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 activation in monocytes accelerates liver cancer progression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMC Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>506</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">W.Y. Wu, J. Li, Z.S. Wu, C.L. Zhang, X.L. Meng, STAT3 activation in monocytes accelerates liver cancer progression, BMC Cancer. 11 (2011) 506.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kusaba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakayama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamazumi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yakata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Yoshizaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nagayasu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Sekine</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of STAT3 is a marker of poor prognosis in human colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2006 Jun</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1445</sb:first-page>
                              <sb:last-page>1451</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">T. Kusaba, T. Nakayama, K. Yamazumi, Y. Yakata, A. Yoshizaki, K. Inoue, T. Nagayasu, I. Sekine, Activation of STAT3 is a marker of poor prognosis in human colorectal cancer, Oncol Rep. 2006 Jun;15(6):1445-1451.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Dobi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Monnien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ivanaj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>NâGuyen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Demarchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Adotevi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thierry-Vuillemin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kantelip</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Pivot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Godet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Degano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Borg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Colorectal Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>28</sb:first-page>
                              <sb:last-page>36</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">E. Dobi, F. Monnien, S. Kim, A. Ivanaj, T. NâGuyen, M. Demarchi, O. Adotevi, A. Thierry-Vuillemin, M. Jary, B. Kantelip, X. Pivot, Y. Godet, S.V. Degano, C. Borg, Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer, Clin Colorectal Cancer. 12 (2013) 28â36.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Diaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Minton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Gritsko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Eweis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wloch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Livingston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Seijo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cantor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Beam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sullivan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Muro-Cacho</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20</sb:first-page>
                              <sb:last-page>28</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">N. Diaz, S. Minton, C. Cox, T. Bowman, T. Gritsko, R. Garcia, I. Eweis, M. Wloch, S. Livingston, E. Seijo, A. Cantor, J.H. Lee, C.A. Beam, D. Sullivan, R. Jove, C.A. Muro-Cacho, Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression, Clin Cancer Res. 12 (2006) 20â28.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinicopathological and prognostic role of STAT3/p-STAT3 in breast cancer patients in China: a meta-analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11243</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Y. Li, Y. Wang, Z. Shi, J. Liu, S. Zheng, J. Yang, Y. Liu, Y. Yang, F. Chang, W. Yu, Clinicopathological and prognostic role of STAT3/p-STAT3 in breast cancer patients in China: A meta-analysis, Sci Rep. 9 (2019) 11243.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Min</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wei-hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Obstet. Gynaecol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>918</sb:first-page>
                              <sb:last-page>925</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">H. Min, Z. Wei-hong, Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma, J Obstet Gynaecol Res. 35 (2009) 918â925.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The prognostic values of signal transducers activators of transcription family in ovarian cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biosci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:article-number>BSR20170650</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">S. Li, B. Sheng, M. Zhao, Q. Shen, H. Zhu, X. Zhu, The prognostic values of signal transducers activators of transcription family in ovarian cancer, Biosci Rep. 37 (2017) BSR20170650.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Settleman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>207</sb:first-page>
                              <sb:last-page>221</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">H.J. Lee, G. Zhuang, Y. Cao, P. Du, H.J. Kim, J. Settleman, Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells, Cancer Cell 26 (2014) 207â221.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Feedback activation of STAT3 as a cancer drug-resistance mechanism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>47</sb:first-page>
                              <sb:last-page>61</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">C. Zhao, H. Li, H.J. Lin, S. Yang, J. Lin, G. Liang, Feedback activation of STAT3 as a cancer drug-resistance mechanism, Trends Pharmacol Sci. 37 (2016) 47â61.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Mahdi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Egwuagu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SOCS3 deletion in T lymphocytes suppresses development of chronic ocular inflammation via upregulation of CTLA-4 and expansion of regulatory T cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>191</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5036</sb:first-page>
                              <sb:last-page>5043</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">C.R. Yu, S.H. Kim, R.M. Mahdi, C.E. Egwuagu, SOCS3 deletion in T lymphocytes suppresses development of chronic ocular inflammation via upregulation of CTLA-4 and expansion of regulatory T cells, J Immunol. 191 (2013) 5036â5043.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Marzec</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goradia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.N.</ce:given-name>
                                 <ce:surname>Raghunath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Paessler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wysocka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Ruggeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Wasik</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>105</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20852</sb:first-page>
                              <sb:last-page>20857</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">M. Marzec, Q. Zhang, A. Goradia, P.N. Raghunath, X. Liu, M. Paessler, H.Y. Wang, M. Wysocka, M. Cheng, B.A. Ruggeri, M.A. Wasik, Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1), Proc Natl Acad Sci USA. 105 (2008) 20852â20857.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Leng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5952</sb:first-page>
                              <sb:last-page>5966</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">A. Li, P. Chen, Y. Leng, J. Kang, Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway, Oncogene 37 (2018) 5952â5966.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sansone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the interleukin-6/Jak/Stat pathway in human malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1005</sb:first-page>
                              <sb:last-page>1014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">P. Sansone, J. Bromberg, Targeting the interleukin-6/Jak/Stat pathway in human malignancies, J Clin Oncol. 30 (2012) 1005â1014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>McCormick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Connolly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Balogh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Veale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Fearon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Rheum. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>74</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1275</sb:first-page>
                              <sb:last-page>1283</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">W. Gao, J. McCormick, M. Connolly, E. Balogh, D.J. Veale, U. Fearon, Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis, Ann Rheum Dis. 74 (2015) 1275â1283.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Leppkes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Neurath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Immune deficiency vs. immune excess in inflammatory bowel diseases-STAT3 as a rheo-STAT of intestinal homeostasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Leukoc. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>99</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>57</sb:first-page>
                              <sb:last-page>66</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">M. Leppkes, M.F. Neurath, M. Herrmann, C. Becker, Immune deficiency vs. immune excess in inflammatory bowel diseases-STAT3 as a rheo-STAT of intestinal homeostasis, J Leukoc Biol. 99 (2016) 57â66.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Hillmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Watowich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 signaling in immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine Growth Factor Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>15</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">E.J. Hillmer, H. Zhang, H.S. Li, S.S. Watowich, STAT3 signaling in immunity, Cytokine Growth Factor Rev. 31 (2016) 1â15.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Miyoshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Takaishi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nakajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ikeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tarutani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Iiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Asao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>DiGiovanni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Invest. Dermatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>108</sb:first-page>
                              <sb:last-page>117</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">K. Miyoshi, M. Takaishi, K. Nakajima, M. Ikeda, T. Kanda, M. Tarutani, T. Iiyama, N. Asao, J. DiGiovanni, S. Sano, Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor, J Invest Dermatol. 131 (2011) 108â117.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Nielsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Clausen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5</sb:first-page>
                              <sb:last-page>10</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">P. Wu, T.E. Nielsen, M.H. Clausen, Small-molecule kinase inhibitors: an analysis of FDA-approved drugs, Drug Discov Today. 21 (2016) 5â10.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Rosenzweig</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acquired resistance to drugs targeting tyrosine kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>71</sb:first-page>
                              <sb:last-page>98</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">S.A. Rosenzweig, Acquired resistance to drugs targeting tyrosine kinases, Adv Cancer Res. 138 (2018) 71â98.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pireddu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Urlam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Guida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1922</sb:first-page>
                              <sb:last-page>1933</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">X. Zhang, Y. Sun, R. Pireddu, H. Yang, M.K. Urlam, H.R. Lawrence, W.C. Guida, N.J. Lawrence, S.M. Sebti, A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation, Cancer Res. 73 (2013) 1922â1933.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Clausen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Nielsen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Allosteric small-molecule kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>156</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                              <sb:last-page>68</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">P. Wu, M.H. Clausen, T.E. Nielsen, Allosteric small-molecule kinase inhibitors, Pharmacol Ther. 156 (2015) 59â68.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.V.</ce:given-name>
                                 <ce:surname>Dokholyan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Controlling allosteric networks in proteins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6463</sb:first-page>
                              <sb:last-page>6487</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">N.V. Dokholyan, Controlling Allosteric Networks in Proteins, Chem Rev. 116 (2016) 6463â6487.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nussinov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Radivojac</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Allosteric post-translational modification codes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Biochem. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>447</sb:first-page>
                              <sb:last-page>455</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">R. Nussinov, C.J. Tsai, F. Xin, P. Radivojac, Allosteric post-translational modification codes, Trends Biochem Sci. 37 (2012) 447â455.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Gorman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>DâAmico</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Winston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Boehr</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Engineering allostery into proteins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Exp. Med. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1163</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>359</sb:first-page>
                              <sb:last-page>384</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">S.D. Gorman, R.N. DâAmico, D.S. Winston, D.D. Boehr, Engineering allostery into proteins, Adv Exp Med Biol. 1163 (2019) 359â384.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein allostery and conformational dynamics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6503</sb:first-page>
                              <sb:last-page>6515</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">J. Guo, H.X. Zhou, Protein allostery and conformational dynamics, Chem Rev. 116 (2016) 6503â6515.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.P.</ce:given-name>
                                 <ce:surname>Lisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Loria</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Allostery in enzyme catalysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Struct. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>123</sb:first-page>
                              <sb:last-page>130</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">G.P. Lisi, J.P. Loria, Allostery in enzyme catalysis, Curr Opin Struct Biol. 47 (2017) 123â130.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wootten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Christopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Sexton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Emerging paradigms in GPCR allostery: implications for drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>630</sb:first-page>
                              <sb:last-page>644</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">D. Wootten, A. Christopoulos, P.M. Sexton, Emerging paradigms in GPCR allostery: implications for drug discovery, Nat Rev Drug Discov. 12 (2013) 630â644.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>385</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>51</sb:first-page>
                              <sb:last-page>54</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">S. Wang, Y. Song, D. Liu, EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance, Cancer Lett. 385 (2017) 51â54.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Hunt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Herrgard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ciceri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Wodicka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Pallares</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hocker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Treiber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Zarrinkar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comprehensive analysis of kinase inhibitor selectivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1046</sb:first-page>
                              <sb:last-page>1051</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, P.P. Zarrinkar, Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 29 (2011) 1046â1051.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yueh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rettenmaier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Hall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Alekseenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Porter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Barkovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Keseru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Whitty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Vajda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kozakov</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase Atlas: druggability analysis of potential allosteric sites in kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6512</sb:first-page>
                              <sb:last-page>6524</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">C. Yueh, J. Rettenmaier, B. Xia, D.R. Hall, A. Alekseenko, K.A. Porter, K. Barkovich, G. Keseru, A. Whitty, J.A. Wells, S. Vajda, D. Kozakov, Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases, J Med Chem. 62 (2019) 6512â6524.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Ostrem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Peters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Sos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Shokat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>KÂ Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>503</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>548</sb:first-page>
                              <sb:last-page>551</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">J.M. Ostrem, U. Peters, M.L. Sos, J.A. Wells, K.M. Shokat, K Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature 503 (2013) 548-551.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.V.</ce:given-name>
                                 <ce:surname>Dang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Shokat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Soucek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drugging the âundruggableâ cancer targets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>502</sb:first-page>
                              <sb:last-page>508</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">C.V. Dang, E.P. Reddy, K.M. Shokat, L. Soucek, Drugging the âundruggableâ cancer targets, Nat Rev Cancer. 17 (2017) 502-508.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pricer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Gestwicki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Mapp</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>From fuzzy to function: the new frontier of protein-protein interactions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acc. Chem. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>50</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>584</sb:first-page>
                              <sb:last-page>589</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">R. Pricer, J.E. Gestwicki, A.K. Mapp, From fuzzy to function: The new frontier of protein-protein interactions, Acc Chem Res. 50 (2017) 584-589.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bronte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rolfo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Giovannetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cicero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Pauwels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Passiglia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Castiglia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rizzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.L.</ce:given-name>
                                 <ce:surname>Vullo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fiorentino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Van Meerbeeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Russo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Crit. Rev. Oncol. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>89</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>300</sb:first-page>
                              <sb:last-page>313</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">G. Bronte, C. Rolfo, E. Giovannetti, G. Cicero, P. Pauwels, F. Passiglia, M. Castiglia, S. Rizzo, F.L. Vullo, E. Fiorentino, J. Van Meerbeeck, A. Russo, Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects, Crit Rev Oncol Hematol. 89 (2014) 300-313.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ambrogio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Shimamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kubo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Chirieac</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Padera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.I.</ce:given-name>
                                 <ce:surname>Shapiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Baum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Himmelsbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Rettig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Meyerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Solca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Greulich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4702</sb:first-page>
                              <sb:last-page>4711</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, L.R. Chirieac, R.F. Padera, G.I. Shapiro, A. Baum, F. Himmelsbach, W.J. Rettig, M. Meyerson, F. Solca, H. Greulich, K.K. Wong, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene 27 (2008) 4702-4711.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Sundaresan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.V.</ce:given-name>
                                 <ce:surname>Sequist</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.V.</ce:given-name>
                                 <ce:surname>Heymach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Riely</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>JÃ¤nne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Koch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Sullivan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Fox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Maher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Muzikansky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Webb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.T.</ce:given-name>
                                 <ce:surname>Tran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Giri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fleisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Barber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Walsh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Engelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Stott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kapur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Maheswaran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Toner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Haber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1103</sb:first-page>
                              <sb:last-page>1110</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">T.K. Sundaresan, L.V. Sequist, J.V. Heymach, G.J. Riely, P.A. Janne, W.H. Koch, J.P. Sullivan, D.B. Fox, R. Maher, A. Muzikansky, A. Webb, H.T. Tran, U. Giri, M. Fleisher, H.A. Yu, W. Wei, B.E. Johnson, T.A. Barber, J.R. Walsh, J.A. Engelman, S.L. Stott, R. Kapur, S. Maheswaran, M. Toner, D.A. Haber, Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses, Clin Cancer Res. 22 (2016) 1103-1110.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Niederst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Mulvey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Lockerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Piotrowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.V.</ce:given-name>
                                 <ce:surname>Sequist</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Engelman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3924</sb:first-page>
                              <sb:last-page>3933</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">M.J. Niederst, H. Hu, H.E. Mulvey, E.L. Lockerman, A.R. Garcia, Z. Piotrowska, L.V. Sequist, J.A. Engelman, The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies, Clin Cancer Res. 21 (2015) 3924-3933.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ercan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Manuia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Juarez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Rhee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Palakurthi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lelais</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>DiDonato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Bursulaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.Y.</ce:given-name>
                                 <ce:surname>Michellys</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Epple</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Marsilje</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>McNeil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bender</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>JÃ¤nne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>534</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>129</sb:first-page>
                              <sb:last-page>132</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">Y. Jia, C.H. Yun, E. Park, D. Ercan, M. Manuia, J. Juarez, C. Xu, K. Rhee, T. Chen, H. Zhang, S. Palakurthi, J. Jang, G. Lelais, M. DiDonato, B. Bursulaya, P.Y. Michellys, R. Epple, T.H. Marsilje, M. McNeil, W. Lu, J. Harris, S. Bender, K.K. Wong, P.A. Janne, M.J. Eck, Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors, Nature 534 (2016) 129-132.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>To</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mushajiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.H.</ce:given-name>
                                 <ce:surname>De Clercq</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Cameron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Heppner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Gero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Dahlberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>JÃ¤nne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Single and dual targeting of mutant EGFR with an allosteric inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>926</sb:first-page>
                              <sb:last-page>943</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">C. To, J. Jang, T. Chen, E. Park, M. Mushajiang, D.J.H. De Clercq, M. Xu, S. Wang, M.D. Cameron, D.E. Heppner, B.H. Shin, T.W. Gero, A. Yang, S.E. Dahlberg, K.K. Wong, M.J. Eck, N.S. Gray, P.A. Janne, Single and dual targeting of mutant EGFR with an allosteric inhibitor, Cancer Discov. 9 (2019) 926-943.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Carlino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Christodoulou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Restelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Caporuscio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Foschi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Semrau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Costanzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tinivella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Pinzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lo Presti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Battistutta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Storici</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Broggini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Passarella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Rastelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-activity relationships of hexahydrocyclopenta[c]quinoline derivatives as allosteric inhibitors of CDK2 and EGFR</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2627</sb:first-page>
                              <sb:last-page>2634</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">L. Carlino, M.S. Christodoulou, V. Restelli, F. Caporuscio, F. Foschi, M.S. Semrau, E. Costanzi, A. Tinivella, L. Pinzi, L. Lo Presti, R. Battistutta, P. Storici, M. Broggini, D. Passarella, G. Rastelli, Structure-activity relationships of hexahydrocyclopenta[c]quinoline derivatives as allosteric inhibitors of CDK2 and EGFR, ChemMedChem 13 (2018) 2627-2634.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Caporuscio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tinivella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Restelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Semrau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Pinzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Storici</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Broggini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Rastelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1545</sb:first-page>
                              <sb:last-page>1553</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">F. Caporuscio, A. Tinivella, V. Restelli, M.S. Semrau, L. Pinzi, P. Storici, M. Broggini, G. Rastelli, Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking, Future Med Chem. 10 (2018) 1545-1553.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Cross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Claesson-Welsh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>201</sb:first-page>
                              <sb:last-page>207</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">M.J. Cross, L. Claesson-Welsh, FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition, Trends Pharmacol Sci. 22 (2001) 201-207.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Cheuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Shern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.K.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Hurd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PloS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:article-number>e76551</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">S.Q. Li, A.T. Cheuk, J.F. Shern, Y.K. Song, L. Hurd, H. Liao, J.S. Wei, J. Khan, Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One 8 (2013) e76551.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.T.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Shiau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5189</sb:first-page>
                              <sb:last-page>5199</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">K.F. Chen, W.T. Tai, T.H. Liu, H.P. Huang, Y.C. Lin, C.W. Shiau, P.K. Li, P.J. Chen, A.L. Cheng, Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3, Clin Cancer Res. 16 (2010) 5189-5199.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Villanueva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Llovet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1824</sb:first-page>
                              <sb:last-page>1826</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">A. Villanueva, J.M. Llovet, Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib, Clin Cancer Res. 18 (2012) 1824-1826.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>De Smet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Herbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>De Bock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Georgiadou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Fons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tjwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Alcouffe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bianciotto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Jonckx</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Murakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Lanahan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Michielsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sibrac</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Dol-Gleizes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mazzone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zacchigna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Herault</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rigon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ruiz de Almodovar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Claes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Blanc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Poesen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Segura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gueguen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Bordes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lambrechts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Broussy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>van de Wouwer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Michaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Shimada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Jean</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Blacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Noel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Motte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Rom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Rakic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Katsuma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Schaeffer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Yayon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Van Schepdael</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Schwalbe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.L.</ce:given-name>
                                 <ce:surname>Gervasio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Carmeliet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rozensky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dewerchin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Simons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Christopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Herbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Carmeliet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>477</sb:first-page>
                              <sb:last-page>488</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">F. Bono, F. De Smet, C. Herbert, K. De Bock, M. Georgiadou, P. Fons, M. Tjwa, C. Alcouffe, A. Ny, M. Bianciotto, B. Jonckx, M. Murakami, A.A. Lanahan, C. Michielsen, D. Sibrac, F. Dol-Gleizes, M. Mazzone, S. Zacchigna, J.P. Herault, C. Fischer, P. Rigon, C. Ruiz de Almodovar, F. Claes, I. Blanc, K. Poesen, J. Zhang, I. Segura, G. Gueguen, M.F. Bordes, D. Lambrechts, R. Broussy, M. van de Wouwer, C. Michaux, T. Shimada, I. Jean, S. Blacher, A. Noel, P. Motte, E. Rom, J.M. Rakic, S. Katsuma, P. Schaeffer, A. Yayon, A. Van Schepdael, H. Schwalbe, F.L. Gervasio, G. Carmeliet, J. Rozensky, M. Dewerchin, M. Simons, A. Christopoulos, J.M. Herbert, P. Carmeliet, Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties, Cancer Cell. 23 (2013) 477-488.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>OâShea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kontzias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamaoka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laurence</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Janus kinase inhibitors in autoimmune diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Rheum. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111</sb:first-page>
                              <sb:last-page>115</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">J.J. OâShea, A. Kontzias, K. Yamaoka, Y. Tanaka, A. Laurence, Janus kinase inhibitors in autoimmune diseases, Ann Rheum Dis. 72 (2013) 111-115.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>OâHare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Walters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Stoffregen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Sherbenou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Druker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6987</sb:first-page>
                              <sb:last-page>6993</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">T. OâHare, D.K. Walters, E.P. Stoffregen, D.W. Sherbenou, M.C. Heinrich, M.W. Deininger, B.J. Druker, Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib, Clin Cancer Res. 11 (2005) 6987-6993.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Buchert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Burns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ernst</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting JAK kinase in solid tumors: emerging opportunities and challenges</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>939</sb:first-page>
                              <sb:last-page>951</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">M. Buchert, C.J. Burns, M. Ernst, Targeting JAK kinase in solid tumors: emerging opportunities and challenges, Oncogene 35 (2016) 939-951.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factor STAT3 as a novel molecular target for cancer prevention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>926</sb:first-page>
                              <sb:last-page>957</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">A. Xiong, Z. Yang, Y. Shen, J. Zhou, Q. Shen, Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers 6 (2014) 926-957.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.N.</ce:given-name>
                                 <ce:surname>Puls</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Eadens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Messersmith</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Current status of Src inhibitors in solid tumor malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>566</sb:first-page>
                              <sb:last-page>578</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">L.N. Puls, M. Eadens, W. Messersmith, Current status of Src inhibitors in solid tumor malignancies, Oncologist 16 (2011) 566-578.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Buchert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Burns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ernst</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting JAK kinase in solid tumors: emerging opportunities and challenges</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>939</sb:first-page>
                              <sb:last-page>951</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">M. Buchert, C.J. Burns, M. Ernst, Targeting JAK kinase in solid tumors: emerging opportunities and challenges, Oncogene 35 (2016) 939-951.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.K.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.D.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.F.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Q.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic potential of tyrosine kinase 2 in autoimmunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>571</sb:first-page>
                              <sb:last-page>580</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0380">Y. Liang, Y. Zhu, Y. Xia, H. Peng, X.K. Yang, Y.Y. Liu, W.D. Xu, H.F. Pan, D.Q. Ye, Therapeutic potential of tyrosine kinase 2 in autoimmunity, Expert Opin Ther Targets. 18 (2014) 571-580.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Min</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ungureanu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Maxwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>HammarÃ©n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Thibault</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.K.</ce:given-name>
                                 <ce:surname>Hillert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ayres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Greenfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Eksterowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gabel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silvennoinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>290</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>27261</sb:first-page>
                              <sb:last-page>27270</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0385">X. Min, D. Ungureanu, S. Maxwell, H. Hammaren, S. Thibault, E.K. Hillert, M. Ayres, B. Greenfield, J. Eksterowicz, C. Gabel, N. Walker, O. Silvennoinen, Z. Wang, Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2), J Biol Chem. 290 (2015) 27261-27270.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zupa-Fernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Tredup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Pike</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pedicord</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Muckelbauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Edavettal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Witmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Elkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Blat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Pitts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>290</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11061</sb:first-page>
                              <sb:last-page>11074</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0390">J.S. Tokarski, A. Zupa-Fernandez, J.A. Tredup, K. Pike, C. Chang, D. Xie, L. Cheng, D. Pedicord, J. Muckelbauer, S.R. Johnson, S. Wu, S.C. Edavettal, Y. Hong, M.R. Witmer, L.L. Elkin, Y. Blat, W.J. Pitts, D.S. Weinstein, J.R. Burke, Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain, J Biol Chem. 290 (2015) 11061-11074.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moslin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gardner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Santella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.V.</ce:given-name>
                                 <ce:surname>Duncia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pedicord</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Blat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zupa-Fernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chaudhry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>DâArienzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Sack</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Muckelbauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tredup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Aranibar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of imidazo [1, 2-b] pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Medchemcomm</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>700</sb:first-page>
                              <sb:last-page>712</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0395">R. Moslin, D. Gardner, J. Santella, Y. Zhang, J.V. Duncia, C. Liu, J. Lin, J.S. Tokarski, J. Strnad, D. Pedicord, J. Chen, Y. Blat, A. Zupa-Fernandez, L. Cheng, H. Sun, C. Chaudhry, C. Huang, C. DâArienzo, J.S. Sack, J.K. Muckelbauer, C. Chang, J. Tredup, D. Xie, N. Aranibar, J.R. Burke, P.H. Carter, D.S. Weinstein, Identification of imidazo [1, 2-b] pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling, Medchemcomm. 8 (2016) 700-712.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Wrobleski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moslin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Spergel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kempson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Strnad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zupa-Fernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Shuster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Gillooly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Heimrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>McIntyre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chaudhry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ruzanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tredup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mulligan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>DâArienzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Aranibar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chiney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chimalakonda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Pitts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8973</sb:first-page>
                              <sb:last-page>8995</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0400">S.T. Wrobleski, R. Moslin, S. Lin, Y. Zhang, S. Spergel, J. Kempson, J.S. Tokarski, J. Strnad, A. Zupa-Fernandez, L. Cheng, D. Shuster, K. Gillooly, X. Yang, E. Heimrich, K.W. McIntyre, C. Chaudhry, J. Khan, M. Ruzanov, J. Tredup, D. Mulligan, D. Xie, H. Sun, C. Huang, C. DâArienzo, N. Aranibar, M. Chiney, A. Chimalakonda, W.J. Pitts, L. Lombardo, P.H. Carter, J.R. Burke, D.S. Weinstein, Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165, J Med Chem. 62 (2019) 8973-8995.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.B.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tucker-Burden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.E.</ce:given-name>
                                 <ce:surname>McDonald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.W.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.A.</ce:given-name>
                                 <ce:surname>Weiss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Brat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Blockade of glioma proliferation through allosteric inhibition of JAK2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>ra55</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0405">K. He, Q. Qi, C.B. Chan, G. Xiao, X. Liu, C. Tucker-Burden, L. Wang, H. Mao, X. Lu, F.E. McDonald, H. Luo, Q.W. Fan, W.A. Weiss, S.Y. Sun, D.J. Brat, K. Ye, Blockade of glioma proliferation through allosteric inhibition of JAK2, Sci Signal. 6 (2013) ra55.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <sb:reference id="sref79">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>3-Deoxy-2Î²,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Pharmacol. Sin.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>40</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1578</sb:first-page>
                              <sb:last-page>1586</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0410">H. Shan, S. Yao, Y. Ye, Q. Yu, 3-Deoxy-2Î²,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells, Acta Pharmacol Sin. 40 (2019) 1578-1586.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Coppo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Flamant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>De Mas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jarrier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guillier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Bonnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lacout</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Guilhot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Vainchenker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Turhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BCR-ABL activates STAT3 via JAK and MEK pathways in human cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>134</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>171</sb:first-page>
                              <sb:last-page>179</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0415">P. Coppo, S. Flamant, V. De Mas, P. Jarrier, M. Guillier, M.L. Bonnet, C. Lacout, F. Guilhot, W. Vainchenker, A.G. Turhan, BCR-ABL activates STAT3 via JAK and MEK pathways in human cells, Br J Haematol. 134 (2006) 171-179.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Kizilbash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Zaidi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Alruwaili</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shahzad</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Differences in structural elements of Bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioinformation</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>108</sb:first-page>
                              <sb:last-page>114</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0420">A. Hai, N.A. Kizilbash, S.H. Zaidi, J. Alruwaili, K. Shahzad, Differences in structural elements of Bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia, Bioinformation 10 (2014) 108-114.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Talpaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Giles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>OâBrien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Intern. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>145</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>913</sb:first-page>
                              <sb:last-page>923</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0425">H.M. Kantarjian, M. Talpaz, F. Giles, S. OâBrien, J. Cortes, New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 145 (2006) 913-923.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>AdriÃ¡n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Velentza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sloan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Manley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mestan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Fabbro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Allosteric inhibitors of Bcr-abl-dependent cell proliferation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>95</sb:first-page>
                              <sb:last-page>102</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0430">F.J. Adrian, Q. Ding, T. Sim, A. Velentza, C. Sloan, Y. Liu, G. Zhang, W. Hur, S. Ding, P. Manley, J. Mestan, D. Fabbro, N.S. Gray, Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2 (2006) 95-102.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Wylie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schoepfer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jahnke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Cowan-Jacob</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Loo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Furet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Marzinzik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Pelle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Donovan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Buonamici</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.Q.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lombardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Iyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Palmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Berellini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dodd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Thohan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Bitter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Branford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Ross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Petruzzelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.G.</ce:given-name>
                                 <ce:surname>Vanasse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Warmuth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hofmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Keen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.R.</ce:given-name>
                                 <ce:surname>Sellers</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>543</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>733</sb:first-page>
                              <sb:last-page>737</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0435">A.A. Wylie, J. Schoepfer, W. Jahnke, S.W. Cowan-Jacob, A. Loo, P. Furet, A.L. Marzinzik, X. Pelle, J. Donovan, W. Zhu, S. Buonamici, A.Q. Hassan, L. Lombardo, V. Iyer, M. Palmer, G. Berellini, S. Dodd, S. Thohan, H. Bitter, S. Branford, D.M. Ross, T.P. Hughes, L. Petruzzelli, K.G. Vanasse, M. Warmuth, F. Hofmann, N.J. Keen, W.R. Sellers, The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1, Nature 543 (2017) 733-737.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Mauro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Minami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Rea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>DeAngelo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Breccia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Talpa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hochhaus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>le Coutre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Ottmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Steegmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.N.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.W.M.</ce:given-name>
                                 <ce:surname>Janssen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.X.</ce:given-name>
                                 <ce:surname>Mahon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Minami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Yeung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Ross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Tallman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Druker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hynds</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Meille</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hourcade-Potelleret</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.G.</ce:given-name>
                                 <ce:surname>Vanasse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N.Â Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>381</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2315</sb:first-page>
                              <sb:last-page>2326</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0440">T.P. Hughes, M.J. Mauro, J.E. Cortes, H. Minami, D. Rea, D.J. DeAngelo, M. Breccia, Y.T. Goh, M. Talpa, A. Hochhaus, P. le Coutre, O. Ottmann, M.C. Heinrich, J.L. Steegmann, M.W.N. Deininger, J.J.W.M. Janssen, F.X. Mahon, Y. Minami, D. Yeung, D.M. Ross, M.S. Tallman, J.H. Park, B.J. Druker, D. Hynds, Y. Duan, C. Meille, F. Hourcade-Potelleret, K.G. Vanasse, F. Lang, D.W. Kim, Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure, N Engl J Med. 381 (2019) 2315-2326.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Treatment selection for Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chemotherapy</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>64</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>81</sb:first-page>
                              <sb:last-page>93</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0445">Y. Ma, Q. Zhang, P. Kong, J. Xiong, X. Zhang, C. Zhang, Treatment selection for Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors, Chemotherapy 64 (2019) 81-93.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Crespan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Radi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zanoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schenone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Botta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Maga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual Src and Abl inhibitors target wild type Abl and the Abl<ce:sup loc="post">T315I</ce:sup> imatinib-resistant mutant with different mechanisms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3999</sb:first-page>
                              <sb:last-page>4008</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0450">E. Crespan, M. Radi, S. Zanoli, S. Schenone, M. Botta, G. Maga, Dual Src and Abl inhibitors target wild type Abl and the AblT315I imatinib-resistant mutant with different mechanisms, Bioorg Med Chem. 18 (2010) 3999-4008.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Vignaroli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mencarelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sementa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Crespan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kissova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Maga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schenone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Radi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Botta</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploring the chemical space around the privileged pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine scaffold: toward novel allosteric inhibitors of T315I-mutated Abl</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Comb. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>168</sb:first-page>
                              <sb:last-page>175</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0455">G. Vignaroli, M. Mencarelli, D. Sementa, E. Crespan, M. Kissova, G. Maga, S. Schenone, M. Radi, M. Botta, Exploring the chemical space around the privileged pyrazolo[3,4-d]pyrimidine scaffold: toward novel allosteric inhibitors of T315I-mutated Abl, ACS Comb. Sci. 16 (2014) 168â175.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.H.</ce:given-name>
                                 <ce:surname>Gelman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Src-family tyrosine kinases as therapeutic targets in advanced cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Biosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>801</sb:first-page>
                              <sb:last-page>807</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0460">I.H. Gelman, Src-family tyrosine kinases as therapeutic targets in advanced cancer. Front Biosci 3 (2011) 801-807.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Shukla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Roux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.S.</ce:given-name>
                                 <ce:surname>Pande</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation pathway of Src kinase reveals intermediate states as targets for drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3397</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0465">D. Shukla, Y. Meng, B. Roux, V.S. Pande, Activation pathway of Src kinase reveals intermediate states as targets for drug design, Nat Commun. 5 (2014) 3397.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Yeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3-interacting proteins as modulators of transcription factor function: implications to targeted cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>795</sb:first-page>
                              <sb:last-page>801</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0470">J.E. Yeh, D.A. Frank, STAT3-interacting proteins as modulators of transcription factor function: implications to targeted cancer therapy, ChemMedChem 11 (2016) 795-801.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="sref92">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Namanja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Colson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Allosteric communication across STAT3 domains associated with STAT3 function and disease-causing mutation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>428</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>579</sb:first-page>
                              <sb:last-page>589</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0475">A.T. Namanja, J. Wang, R. Buettner, L. Colson, Y. Chen, Allosteric communication across STAT3 domains associated with STAT3 function and disease-causing mutation, J Mol Biol. 428 (2016) 579-589.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <sb:reference id="sref93">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Gong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>294</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>17471</sb:first-page>
                              <sb:last-page>17486</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0480">X. Shen, L. Zhao, P. Chen, Y. Gong, D. Liu, X. Zhang, L. Dai, Q. Sun, J. Lou, Z. Jin, B. Zhang, D. Niu, C. Chen, X. Qi, D. Jia, A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3. J Biol Chem. 294 (2019) 17471-17486.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Butturini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Darra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chiavegato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Cellini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cozzolino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Monti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Pucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>DellâOrco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mariotto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>S-glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1885</sb:first-page>
                              <sb:last-page>1893</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0485">E. Butturini, E. Darra, G. Chiavegato, B. Cellini, F. Cozzolino, M. Monti, P. Pucci, D. DellâOrco, S. Mariotto, S-glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation, ACS Chem Biol. 9 (2014) 1885-1893.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Minus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vohidov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Kasembeli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Krueger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Stevens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Kolosov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Tweardy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Sison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Redell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.T.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rhodium (II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew Chem. Int. Ed. Engl.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13085</sb:first-page>
                              <sb:last-page>13089</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0490">M.B. Minus, W. Liu, F. Vohidov, M.M. Kasembeli, X. Long, M.J. Krueger, A. Stevens, M.I. Kolosov, D.J. Tweardy, E.A. Sison, M.S. Redell, Z.T. Ball, Rhodium (II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity, Angew Chem Int Ed Engl. 54 (2015) 13085-13089.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Hardy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Searching for new allosteric sites in enzymes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Struct. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>706</sb:first-page>
                              <sb:last-page>715</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0495">J.A. Hardy, J.A. Wells, Searching for new allosteric sites in enzymes. Curr Opin Struct Biol. 14 (2004) 706-715.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.A.</ce:given-name>
                                 <ce:surname>Feher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Durrant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Van Wart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Amaro</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Computational approaches to mapping allosteric pathways</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Struct. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>98</sb:first-page>
                              <sb:last-page>103</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0500">V.A. Feher, J.D. Durrant, A.T. Van Wart, R.E. Amaro, Computational approaches to mapping allosteric pathways. Curr Opin Struct Biol. 25 (2014) 98-103.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib98">
                     <ce:label>[98]</ce:label>
                     <sb:reference id="sref98">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nucleic Acids Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>451</sb:first-page>
                              <sb:last-page>458</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0505">M. Huang, K. Song, X. Liu, S. Lu, Q. Shen, R. Wang, J. Gao, Y. Hong, Q. Li, D. Ni, J. Xu, G. Chen, J. Zhang, AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses, Nucleic Acids Res. 46 (2018) 451-458.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib99">
                     <ce:label>[99]</ce:label>
                     <sb:reference id="sref99">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Allosteric modulator discovery: from serendipity to structure-based design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6405</sb:first-page>
                              <sb:last-page>6421</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0510">S. Lu, X. He, D. Ni, J. Zhang, Allosteric modulator discovery: from serendipity to structure-based design, J Med Chem. 62 (2019) 6405-6421.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib100">
                     <ce:label>[100]</ce:label>
                     <sb:reference id="sref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Akbay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Koyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Carretero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Altabef</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Tchaicha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Christensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.R.</ce:given-name>
                                 <ce:surname>Mikse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Cherniack</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Beauchamp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Pugh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Wilkerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Fecci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Butaney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Reibel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Soucheray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Cohoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Janne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Meyerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.N.</ce:given-name>
                                 <ce:surname>Hayes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.I.</ce:given-name>
                                 <ce:surname>Shapiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Shimamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Sholl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Rodig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Freeman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Hammerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Dranoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1355</sb:first-page>
                              <sb:last-page>1363</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0515">E.A. Akbay, S. Koyama, J. Carretero, A. Altabef, J.H. Tchaicha, C.L. Christensen, O.R. Mikse, A.D. Cherniack, E.M. Beauchamp, T.J. Pugh, M.D. Wilkerson, P.E. Fecci, M. Butaney, J.B. Reibel, M. Soucheray, T.J. Cohoon, P.A. Janne, M. Meyerson, D.N. Hayes, G.I. Shapiro, T. Shimamura, L.M. Sholl, S.J. Rodig, G.J. Freeman, P.S. Hammerman, G. Dranoff, K.K. Wong, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, Cancer Discov. 3(2013) 1355-1363.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib101">
                     <ce:label>[101]</ce:label>
                     <sb:reference id="sref101">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Ahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Ahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EGFR TKI combination with immunotherapy in non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expet Opin. Drug Saf.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>465</sb:first-page>
                              <sb:last-page>469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0520">M.J. Ahn, J.M. Sun, S.H. Lee, J.S. Ahn, K. Park, EGFR TKI combination with immunotherapy in non-small cell lung cancer, Expert Opin Drug Saf. 16(2017) 465-469.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib102">
                     <ce:label>[102]</ce:label>
                     <sb:reference id="sref102">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Clausen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Nielsen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Allosteric small-molecule kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>156</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                              <sb:last-page>68</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0525">P. Wu, M.H. Clausen, T.E. Nielsen, Allosteric small-molecule kinase inhibitors, Pharmacol Ther. 156 (2015) 59-68.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib103">
                     <ce:label>[103]</ce:label>
                     <sb:reference id="sref103">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Pendergrass</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Blair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.W.</ce:given-name>
                                 <ce:surname>Fenton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mining for allosteric information: natural mutations and positional sequence conservation in pyruvate kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>IUBMB Life</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>31</sb:first-page>
                              <sb:last-page>38</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0530">D.C. Pendergrass, R. Williams, J.B. Blair, A.W. Fenton, Mining for allosteric information: natural mutations and positional sequence conservation in pyruvate kinase, IUBMB Life 58 (2006) 31-38.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib104">
                     <ce:label>[104]</ce:label>
                     <sb:reference id="sref104">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Stark</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Roles of unphosphorylated STATs in signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>443</sb:first-page>
                              <sb:last-page>451</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0535">J. Yang, G.R. Stark, Roles of unphosphorylated STATs in signaling, Cell Res. 18 (2008) 443-451.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib105">
                     <ce:label>[105]</ce:label>
                     <sb:reference id="sref105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Braunstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Brutsaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schindler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs dimerize in the absence of phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>278</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>34133</sb:first-page>
                              <sb:last-page>34140</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0540">J. Braunstein, S. Brutsaert, R. Olson, C. Schindler, STATs dimerize in the absence of phosphorylation, J. Biol. Chem. 278 (2003) 34133-34140.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib106">
                     <ce:label>[106]</ce:label>
                     <sb:reference id="sref106">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>McBride</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.C.</ce:given-name>
                                 <ce:surname>Reich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8150</sb:first-page>
                              <sb:last-page>8155</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0545">L. Liu, K.M. McBride, N.C. Reich, STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3, Proc. Natl. Acad. Sci. USA 102 (2005) 8150-8155.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib107">
                     <ce:label>[107]</ce:label>
                     <sb:reference id="sref107">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ potent and selective small-molecule degrader of STAT3 achieves complete tumor regression inÂ vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0550">L. Bai, H. Zhou, R. Xu, Y. Zhao, K. Chinnaswamy, D. McEachern, J. Chen, C.Y. Yang, Z. Liu, M. Wang, L. Liu, H. Jiang, B. Wen, P. Kumar, J.L. Meagher, D. Sun, J.A. Stuckey, S. Wang, A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression inÂ vivo, Cancer Cell 36 (2019) 498-511.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>